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Abstract 
 
Objective: Environmental conditions can exacerbate asthmatic children’s symptoms.  
The benefit was examined for Healthy Homes University II, an in-home asthma public 
health program for low-income families which included an assessment for asthma 
triggers; products and services to reduce exposures; and asthma education. 
Design:  Case-Control Study; symptomatic asthmatic participants aged <18 in Lansing, 
Michigan. Program staff assessed homes for asthma triggers and subsequently 
provided products and services to reduce exposures to cockroaches, dust mites, mold, 
tobacco smoke, and other triggers. Asthma education included identification of asthma 
triggers and instructions on specific behaviors to reduce exposures. Controls selected 
from two similar communities. 
Intervention:  250 households received a baseline intervention home visit for health 
education and product installation, and 3 and 6 month post-intervention home visits. A 
subset of households received custom interventions. 
Participants in study: Children < 18 years of age; income < 80% of Area Median 
Income; continuously enrolled in Medicaid for a 25 month period  and had either one ED 
visit or one hospitalization due to asthma during the first 12 months of that 25 month 
period; 40 cases  met the inclusion criteria. 
Outcome measures:  Asthma-related: controller and reliever prescriptions filled, 
controller and reliever prescription costs, outpatient visits, outpatient costs, emergency 
department visits, emergency department costs, inpatient stays, inpatient stay costs, 
overall costs, and intervention costs.  
Results:  There was a significant increase (p=.04) in the overall utilization of asthma-
related controller prescriptions, by an average of 1.2 prescriptions over a 12 month 
period. There was a significant decrease (p=.006) in the utilization of inpatient stays, by 
an average of 0.31 stays over a 12 month period.  There was no statistically significant 
xvii 
 
difference in the cost of controller or reliever prescription, emergency department, 
inpatient stays, outpatient visits, or overall medical costs; the intervention group spent 
$4 more on medical care than the control group.  With outliers removed, a decrease in 
inpatient costs by $694 was significant (p=.04), and the difference in total medical costs 
increased to $620 and approached statistical significance (p=.052).  Intervention costs 
were $1,882 per household, there was no net-benefit to the intervention, as measured 
by a savings in medical costs.   
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Chapter 1 
Statement of the Problem 
1.1. Significance of the Study 
Childhood Asthma is a major public health issue that is costing billions to treat every 
year. An estimated $19.7 billion was spent on asthma in direct and indirect costs in 
2007 in the United States. Almost 24% ($4.7 billion) of this amount was spent on 
preventable hospital visits [1].  
Allergic diseases, including asthma, are the most frequently reported chronic diseases 
in children, affecting more than 6.2 million children under the age of 18 annually in the 
United States [1].  Moreover, asthma prevalence, hospitalizations, and deaths have 
increased steadily among children over the past three decades [2].  The current asthma 
prevalence rate was 47% higher in blacks than in whites in 2011. Moreover, the highest 
prevalence rates for whites and blacks were in the 5-17 age group in 2011 [3].  Asthma 
is also disproportionately associated with poverty, with poor children having a 
prevalence 1.4 times greater than non-poor children; positive health outcomes and 
savings can be expected to disproportionately accrue to children at the highest risk of 
severe asthma [4]. 
According to one study, the annual per capita employer expenditures for patients with 
asthma are approximately 2.5 times those of people without the disease [5]. Among 
children, the mean health care expenditure for those with asthma is roughly 1.5 times 
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higher compared to those without asthma [6].   Black children have higher rates of 
hospitalization and emergency department (ED) visits than whites, creating a 
disproportionate economic burden of asthma for these populations [7, 8].   
National best practice guidelines for managing asthma, National Asthma Education 
Prevention Program (NAEPP) guidelines[9] outline four best practices of effective 
asthma management. These include: 
i. Use of objective measures of lung function to assess disease severity and  
control; 
ii. Comprehensive pharmacologic therapy to reverse and prevent airway 
inflammation and constriction, and to manage exacerbations; 
iii. Patient education and 
iv. Environmental control measures to avoid or eliminate factors that contribute to 
asthma onset and severity. 
Historically, treatment of asthma has focused on the clinical setting through monitoring 
of lung function and medication use (best practices 1 and 2).  Given the poor control of 
asthma in population based surveys [10], research is focusing on the implementation of 
cost-effective education and environmental trigger reduction programs and services 
(best practices 3 and 4). 
The Asthma Network of West Michigan (ANWM) has provided home-based case 
management services to Priority Health’s Medicaid pediatric population on a fee-for-
service basis, and also has contracts with four other health plans.  However, the current 
reimbursement agreements do not cover the full costs of the programs, and do not 
include best practice 4, the implementation of environmental control measures.  The 
cost-effectiveness of these measures have yet to be demonstrated in Michigan. If they 
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can be demonstrated, the expected contribution is lower health care costs and improved 
health outcomes for children with asthma in Michigan. 
Few patients have access to best practices 3 and 4, patient education and control of 
environmental triggers.  It is known that environmental conditions within the home can 
exacerbate asthmatic children’s symptoms.  As a result, in-home environmental public 
health intervention programs that address multiple environmental triggers combined 
with face-to-face education over multiple home visits have become current program 
practice.  However, many of these initiatives have been grant funded and time-limited, 
and financial sustainability for such programs remains a challenge.  
Little is known about the full costs and benefits of Health Homes Intervention programs 
to control chronic diseases such as asthma in Michigan.   
1.2. Gaps in knowledge 
A CDC Task Force has reviewed 13 studies that evaluated costs and the effectiveness 
of home-based, multi-trigger and multi-component environmental interventions. The 
Task Force Review and selected studies will be discussed in detail in Chapter 2. Briefly, 
the Task Force found that gaps in knowledge remain about how particular components 
impact the overall effectiveness of a multi-faceted intervention [11].   
This analysis will use data from a program that had been funded by the US Department 
of Housing and Urban Development (HUD) in two phases: HHU I (2005 -2008) and 
HHU II (2008-2011).  HHU I program findings showed significant decreases in the 
impact that asthma had on children and self-reported, unscheduled acute health care 
utilization [2].   This evaluation of HHU II, will use actual Medicaid data to measure 
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asthma-related health care utilization.  Additionally, the evaluation will compare the 
intervention group to a control group. 
1.3. Research Questions 
The purpose of the project is to determine if a return on investment (ROI) can be 
demonstrated upon analysis of the second round of a program implemented in Lansing, 
Michigan to study the relationship between the Healthy Homes University (HHU) 
interventions and utilization of emergency department, hospitalization, urgent care, 
physician/clinic utilization, and use of controller and rescue medications due to acute 
asthma events.  The project will consider the health benefits and cost-effectiveness of 
asthma programs that supplement quality clinical care with asthma education and 
environmental interventions in the home.   
1.4. Background on Asthma 
1.4.1. Definition and Essential Characteristics 
According to the World Health Organization, asthma is characterized by recurrent 
attacks of breathlessness and wheezing, which vary in severity and frequency from 
person to person, due to inflammation of the air passages in the lungs, so that the nerve 
endings become easily irritated [12]. In an attack, the lining of the passages swell 
causing the airways to narrow and reducing the flow of air in and out of the lungs [12]. 
Recurrent asthma symptoms frequently cause sleeplessness, daytime fatigue, reduced 
activity levels and school and work absenteeism. Asthma has a relatively low fatality 
rate compared to other chronic diseases. 
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1.4.2. Course of development 
Exposure to allergens and irritants can trigger or exacerbate episodes of asthma, 
especially in the home [13].  Common asthma triggers in the home environment include 
dust mites, pets, cockroaches, mice and rats, mold, environmental tobacco smoke, and 
indoor pollutants.  Strategies have been developed to target each trigger respectively 
[13].  
Dust mites are a long established trigger for dust mite sensitive patients, increasing 
asthma symptoms, pulmonary function, and need for medication.  This trigger can be 
removed through the use of allergen-impermeable pillow and mattress covers, using 
bedding cleaned in hot water >130 F, removal and disposal of old carpet, reduction in 
home humidity to <60%, and the washing of stuffed animals weekly [13, 14]. 
Pet allergens, in particular dog and cat, are a second important trigger; removal of pets 
from the home is the most effective method to reduce this allergen. 
Cockroaches are particularly common in the urban environment, and be hard to 
eliminate.  Allergens can be reduced by using “integrated pest management” strategies 
to include removing food and water sources, maintaining clean surfaces and floors, 
sealing trash containers, carefully storing foods, using gel baits for extermination, and 
sealing all cracks and small holes in the residence. 
Mice and rats are also common in inner-city homes, particularly in kitchens.  Integrated 
pest management techniques including filling holes, vacuuming, cleaning, using low-
toxicity pesticides, placing traps, and storing food carefully are highly effective [13]. 
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Mold and exposure to dampness accounts for 21% of the asthma in the U.S. [15]. 
Remediation involves removing mold from hard, non-porous surfaces; discarding mold-
contaminated materials (carpet, ceiling tiles); and addressing the sources responsible 
for mold growth.  
Environmental tobacco smoke is linked to increased risk of developing asthma, 
increased severity, and increased frequency of exacerbations in children with asthma 
[13]. Interventions are targeted to smokers with asthma, or smokers who are parents of 
children with asthma, through smoking cessation programs and air filtration methods to 
reduce the indoor concentration of environmental tobacco smoke [16].  
Indoor pollutants include nitrogen dioxide, particulate matter from biomass combustion 
products, and bacterial endotoxins [17-19]. They are often a trigger for asthma 
exacerbations, most often through the use of gas stoves, wood-burning appliances or 
fireplaces [13, 20]. 
1.4.3. Prevalence and Incidence 
1.4.3.1. Major risk factors 
Allergies, a family history of allergy, and perinatal exposure to tobacco smoke have 
been implicated as risk factors for developing asthma [21]. Factors that can exacerbate 
existing asthma (i.e. can cause or trigger an asthma attack) are much better understood 
and have been described in section 1.3.1.2.  Exacerbations can result from exposure to 
viral upper respiratory infections, pollen, molds, pet dander, cockroaches, dust mites, 
tobacco smoke, wood smoke, household chemicals, workplace exposures and some 
types of air pollution [21]. Also exercise, aggravating conditions that are not properly 
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treated(e.g. rhinitis, gastro esophageal reflux), and stress can also trigger or exacerbate 
existing asthma [21]. The particular triggers that will exacerbate asthma vary by the 
individual. If not treated appropriately, asthma can cause long-term loss of lung function 
and severe outcomes, such as hospitalizations and even death. 
1.4.4. Impact on health and health care 
1.4.4.1. Mortality, disability, morbidity, and quality of life 
Michigan has conducted the Asthma Call‐back Survey since 2005, which collects 
detailed information about asthma symptoms, management, and trigger exposures.  It is 
the only source of Michigan specific asthma information [22]. The data reflected here 
are Michigan specific and represent response years 2008-2010. 
Asthma Symptoms – Children:  According to this survey, 16.8% of children with current 
asthma had asthma symptoms on 9 or more days during the past month.  
Difficulty Sleeping Due to Asthma Symptoms – Children:  20.4% of children with current 
asthma had difficulty sleeping due to asthma symptoms on 2 or more days during the 
past month. The prevalence was 52.2% higher among children ages 0‐9 than children 
ages 10‐17.  
Asthma symptom-free days – Children:  57.9% of children with current asthma 
experienced 14 asthma symptom‐free days during the past 2 weeks.11.2% of children 
with current asthma had asthma symptoms every day of the last 2 weeks. 
Usual activities limited due to asthma – Children:  55.4% of children with current asthma 
experienced limited usual activities due to asthma during the past 12 months. There 
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were no significant differences within age, sex, and race groups; nor within household 
income or respondent education groups. 
Number of school days missed due to asthma - Children: 16.5% of children with current 
asthma missed 6 or more school days due to asthma in the past 12 months due to 
asthma. 54.5% of children with current asthma missed no school days due to asthma in 
the past 12 months due to asthma. 
Asthma Emergency Department/ Urgent Care Visits – Children:  9.2% of children with 
current asthma visited the emergency department or urgent care center for asthma 2 or 
more times during the past 12 months.  
Asthma Hospitalizations – Children: 4.2% of children with current asthma had at least 1 
hospitalization for asthma the past 12 months. There were no significant differences 
within age, sex, or race groups; nor within household income or respondent education 
groups. 
Asthma Action Plans – Children: 45.7% of children with current asthma had received an 
asthma action plan at some point in their life.  
1.4.4.2. Cost, quality, and access 
The Asthma Call-back Survey also provides information regarding access to care, 
quality of care, and some cost barriers to care.  The following data [21] are Michigan 
specific and represent response years 2008-2010: 
Asthma Action Plans – Children: 45.7% of children with current asthma had received an 
asthma action plan at some point in their life.  
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Asthma Management Class – Children: 12.7% of children with current asthma or an 
adult in their household have taken an asthma management class at some point in their 
life.  
Advised to Modify Environment to Improve Asthma – Children: 44.6% of respondents 
for children with current asthma or an adult in their household have been advised by a 
health professional to modify the child’s environment to improve their asthma at some 
point in their life.  The prevalence of having been advised to modify their environment to 
improve asthma for children with current asthma within household was significantly 
higher among respondents who attended some college or graduated from college than 
respondents with less formal education.  
Long Term Control Medication Use – Children: 49.1% of children with current asthma 
had used a long term control medication during the past 3 months. The prevalence of 
using a long term control medication was significantly higher among respondents who 
attended some college or graduated from college than respondents who did not attend 
at least some college.  
Routine Asthma care Visits – Children: 45.4% of children with current asthma had 2 or 
more routine asthma care visits during the past 12 months.  
Influenza Vaccine – Children: 51.6% of children with current asthma had an influenza 
vaccine during the past 12 months. The prevalence of having received an influenza 
vaccination during the past 12 months for children with current asthma was significantly 
greater (46.7%) among respondents who Graduated from College than respondents 
who attended Some College.  
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Cost Barriers To Care for Children:  10.7% of respondents for children with current 
asthma reported experiencing a cost barrier to their asthma care during the past 12 
months. The most frequent type of cost barrier was related to medication; during the 
past 12 months, 8.5% respondents for children with current asthma reported needing 
asthma medication for the child but could not buy it because of cost. 
1.5. Applied Significance 
If cost-effectiveness of the implementation of NAEPP best practices 3 and 4 can be 
demonstrated, a business case of investing in asthma education and in-home 
environmental interventions could be made to health care payers.  Gaps in insurance 
reimbursement and policy implications for payer organizations will be explored.  If health 
insurers routinely reimbursed for these services and supplies, they could become 
standard components of comprehensive asthma management. 
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Chapter 2 
Review of Literature 
2.1. Major analytical approaches 
An analysis of the cost-benefit of a Healthy Homes intervention, while straightforward in 
and of itself is impacted by various factors which affect the eventual adoption of policy 
changes which would shift expenditures from payers of asthma care from a treatment 
model to a preventative (healthy homes) approach. The reduction of childhood asthma 
morbidity and utilization of health care services is complex, and is impacted by selected 
factors in underlying analytical models.  The review of the selected literature is 
organized according to the concept of healthy homes, cost analysis and cost-benefit 
research, policy issues, and insurance/managed care. 
Over sixty-two articles were identified which were relevant to various aspects of this 
study.  These included articles addressing childhood asthma and healthy homes 
interventions in particular; defining asthma cases; the unsustainability of high asthma 
costs; federal support for healthy homes initiatives; prior studies that have evaluated 
costs and the effectiveness of home-based, multi-trigger and multi-component 
environmental interventions.  The link between housing and health was explored as well 
as the substantial housing related disparities which remain, and the ability to focus 
resources on the subpopulations at greatest risk. The use of cost-effectiveness 
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research for U.S public health policy was reviewed, as well as various methods for cost-
effectiveness analysis.  Articles were also reviewed which focused on the health 
economics of asthma, and funding models which could potentially pay for healthy 
homes interventions upstream, especially as it relates to health plans.  
2.2. Concept of Healthy Homes 
2.2.1. Background 
Florence Nightingale, the founder of modern nursing,  stated “The connection between 
the health and the dwelling of the population is one of the most important that exists” 
[23]. A key characteristic of asthma is the role of environmental exposures in the 
initiation of the disease and its development. Therefore, the reduction in environmental 
triggers can determine the difference between its effective management and it being out 
of control [24].  Although the environmental factors present with asthma are found in all 
types of homes, sub-standard home environments, disproportionately occupied by low-
income and minority populations, allow it to flourish.   
The NAEPP guidelines for the diagnosis and management of asthma [14] recognize the 
importance of reducing exposure to indoor environmental asthma triggers. Furthermore, 
the reduction of indoor exposures has been shown to improve clinical outcomes [25, 
26].  In 2009, a federal Healthy Homes Work Group (HHWG), comprised of 
representatives from HUD, DHHS,CDC,EPA, Department of Energy, USDA, and other 
agencies  was formed with the goal of ensuring universal access to safe, affordable, 
and healthy homes [27]. 
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2.2.2. Definition 
 In 2009 the Surgeon General established a call to action to promote healthy 
homes; homes which are sited, designed, built, maintained, and renovated in ways that 
support the health of its residents [23].  The term homes can be single-family homes, 
apartments, townhomes, duplexes, condominiums, or manufactured homes, and also 
includes the land immediately around the home and any other structures on the 
property.  The call focused on the impact of housing on public health and urged a 
coordinated effort to improve housing factors that affect health [27]. 
 Five broad categories are recognized as contributing to adverse health effects in 
a home [28]: 1) Physical conditions, such as heat, cold, energy efficiency, radon 
exposure, noise, inadequate light, ventilation, and fine particulates in the home. 2) 
Chemical conditions such as carbon monoxide, volatile organic chemicals, secondhand 
smoke, and lead. 3) Biological conditions  such as rodents, house dust mites, 
cockroaches and their associated allergens, and humidity and mold. 4) Building and 
equipment conditions, such as accidents and unintentional injuries and access to sewer 
services. 5) Social conditions, such as architectural features related to mental health. 
 Healthy Homes interventions generally consist of two parts: an environmental 
assessment, which uses an assessment survey tool to identify potential indoor 
contaminants; and environmental trigger education and mitigation, which includes 
education on trigger education, and the implementation of mitigation techniques [29]. 
 Environmental mitigation techniques can be implemented at three levels [13]: 
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Major, which includes major structural improvements to the home, such as carpet 
removal, replacement of ventilation systems, or extensive repairs to restore structural 
integrity (e.g.to roof, walls, floors). 
Moderate, which includes the provision of multiple low cost materials with the active 
involvement of a trained home visitor:  providing a fitting mattress and pillows with 
allergen-impermeable covers, installation of small air filters and dehumidifiers, 
integrated pest management, professional cleaning services or equipment, and minor 
repairs of structural integrity. 
Minor, which includes the provision of advice on recommended environmental changes 
and may include the provision of low-cost items such as mattress and pillow allergen-
impermeable covers. 
2.2.3. Health Disparities in Access to Healthy Homes 
The American Housing Survey (AHS) provides prevalence information on the US 
housing quality, at the national and city levels. Significant disparities by race and 
income over time exist with regards to residence in substandard housing. In 2005, AHS 
data reported that 7.5% of non-Hispanic Blacks, and 2.8% of non-Hispanic Whites, 
resided in moderately substandard housing [30].  A study from Seattle/King County 
reported that among children with persistent asthma in households with incomes less 
than 200% of the poverty line, damp conditions were evident in 65% of the homes, and 
mold was visible in 38% of the homes [31].  The experience with childhood lead 
poisoning has shown that effective interventions can reduce such disparities [30]. 
Between 1976 and 2002, the percentage of children’s blood lead levels more than 10 
  
32 
 
micrograms per deciliter fell from 97% to 3.1% among African American children, by 
focusing resources on the subpopulations at greatest risk. 
2.2.4. Strengths and weaknesses of the approach 
The EPA notes that health plans pay a substantial portion of the costs spent annually to 
treat asthma, and is encouraging insurers to incorporate environmental remediation 
management into their disease management programs [29].  Of the four best practice 
components in the NAEPP guidelines, access to best practices 3 and 4, asthma 
education and environmental interventions, remain scarce, despite increasing evidence 
that these practices improve symptoms [11, 24]. 
2.3. Cost Analysis and Cost-Benefit Research 
2.3.1. Background 
Cost-benefit analysis (CBA) has been put forth as the gold standard of economic 
evaluation methods [32].  This analysis converts health outcomes into dollar equivalents 
and compares the costs and consequences (positive and negative) of various 
intervention strategies in monetary terms [33], by subtracting costs from the value of 
benefits to estimate the net benefit of an intervention [34].   This method has been 
widely used in regulatory analyses of environmental health and safety programs, 
especially by OMB for major regulations expected to have economic impacts greater 
than U.S. $100 million[34]. It is important to note that the least resource-interventions 
may be the most cost-effective, but not the most effective [35]. Also, determining which 
type of intervention is most effective for which type of patient is important.  For 
individuals living in environments with multiple or persistently high levels of asthma 
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triggers, or those with low literacy levels, interventions to reduce environments 
exposures can be beneficial [24]. 
2.3.2. Definition 
The summary measure of a CBA can be expressed as a net benefit (costs minus 
benefits), or as a ratio of costs to benefits [33].   
2.3.3. Important considerations 
A very important consideration in any cost-benefit analysis is perspective. The 
perspective taken by any CBA analysis will determine the final ratio of cost effect. The 
costs associated with adverse health as well as the costs and benefits of any 
intervention addressing a health issue are not distributed equally  among various groups 
in society [33]. For example, the perspective of a federal payer (Medicaid for example) 
may be very different than that of a state payer, a managed care organization, an 
employer, or a beneficiary.  Finally, the overall societal perspective is again different, 
and impacts public policy decisions, as prevention strategies that are cost-effective to 
society may not have a positive short-term financial return for payers [34].  The panel on 
Cost-effectiveness in Health and Medicine recommends the societal perspective, which 
is often used in public health [36].  In this approach, all significant costs and health 
effects associated with everyone affected by the intervention are included in the 
analysis regardless of who pays or benefits [32, 33, 36]. The meaning of the term ‘cost-
effective” also varies depending on the perspective; for purchasers of health care it may 
mean in  relation to the relative value of different health care services; for producers of 
health care technologies and programs, it is used to support their marketing claims; 
finally for advocates of particular illness, it is used to garner resource investments [36]. 
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The pharmaceutical industry and managed care organizations have their own 
perspectives as well, all of which may differ from what might be most cost-effective for 
society at large. 
This analysis will be from the perspective of an insurer/payer.  Of interest are the costs 
they will incur in producing or arranging for medical care for their subscribers and 
beneficiaries [36]. As such, the cost categories of interest are the cost of the healthy 
homes intervention, and the changes in medical benefits, such as the direct medical 
costs (office visits, hospitalizations, emergency department visit, diagnostic tests, 
medical supplies, prescription drugs) [33].  Other considerations which will be 
addressed are the study time frame and the analytic horizon.  It is important to note that 
not relevant to the payer is how rapidly a beneficiary can return to work, as they are not 
responsible for the disability payments. 
2.4. Cost-benefit research related to Asthma and Healthy Homes 
There have been a limited number of studies that have compared the economic burden 
of housing-related adverse health outcomes with the resources required to implement 
relevant interventions [33].  Asthma related direct and indirect costs attributable to 
residential exposure in children and adolescents 16 years or younger is estimated at 
more than $1.1 billion annually [37]. Up to 20% of all asthma cases may be attributable 
to dampness and mold, at an annual cost of $4.0 billion [15]. 
A CDC Task Force has reviewed 13 studies that evaluated costs and the effectiveness 
of home-based, multi-trigger and multi-component environmental interventions [38]. 
Seven of the studies only provided program costs, and were not able to report direct 
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medical costs averted, or benefit-cost-ratios. Six studies with minor to moderate 
remediation demonstrated that these interventions provide good value for money 
invested based on substantial returns for money invested and a cost per symptom free 
day that is below the standard cut-off for what is considered cost-effective in the 
literature. Cost-effectiveness studies show a cost of $12 to $57 per additional symptom 
free day [3 randomized control trials; Krieger (2005), Kattan (2005), and Sullivan 
(2002)].  The majority of studies in the economic review were interventions for children 
with asthma, and studies that included adults also included children. 
Cost-benefit studies show a return of $5.3 to $14.0 for each dollar invested [3 studies; 
Oatman (2007), Jowers (2000), and Shelledy (2005)].  These studies all had a pre-post 
study design, used a 12 month follow-up period, and two of them provided information 
on direct medical costs averted.  The third, Jowers, included productivity costs averted. 
Regression to the mean may have played a role in these studies, because participants 
had moderate to severe asthma at the beginning of the study.  The previously 
mentioned randomized controlled trials were more likely to have benefits which were 
more certainly due to the intervention. Those studies could not show a positive cost-
benefit ratio. 
2.5. Policy Implications 
2.5.1. Background 
Recognizing that good health is not merely the result of good medical care, but the 
result of creating conditions in which people can be healthy, it follows that public policy 
can be one of the most effective approaches to protecting and improving the health of 
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the population [39].  The Institute of Medicine (IOM) convened a panel of experts to 
examine the legal and regulatory authority for public health activities, to describe the 
implications for the changing social and policy context for public health laws and 
regulations. They identified some of the legal and policy interventions available to 
improve the public’s health.  These included the power to regulate; the power to tax and 
spend; and the power to modify the built environment. They also encouraged the 
government and private sector to consider health in all places (HIAP) approaches, 
which can act on the social and environmental factors that influence health but are out 
of the control of the health sector [39]. 
2.5.2. Economic analyses and policy 
Economic analyses can be used to make informed decisions about how to allocate 
limited resources in a manner that optimizes value for money [40]. Current decision 
rules have been inadequate to guide choices that would yield the most benefit for the 
population [40].  There are numerous health related interventions available, with 
significant development of health care and pharmaceutical technologies used to treat 
disease, with concurrent rapid growth in costs. Professional and economic incentives 
continue to expand those services, with the share of the U.S. gross domestic product 
devoted to health care growing from 5 to 15% between 1965 and 1995 [36]; and 
currently at 17.9% [12]. Ninety-nine percent of those health care expenditures target 
individual medical care, leaving few resources to target public  health and prevention 
programs that could benefit the entire population [36].  Attention has focused on acute 
concerns rather than on the most efficient methods of promoting health through 
preventative measures. High-tech and profit-generating  disease-control strategies are 
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favored over high-touch strategies such as home visiting and home remediation,  which 
cannot be patented and do not capture the interest of the pro-profit health care industry 
[41]. Certain services are more profitable than others and the relationship between 
profitability of treatments and their outcomes is a topic avoided by administrators [42]. 
Asthma is no exception. The annual cost for a year’s supply of inhaled fluticasone 
propionate (220ug) is approximately $2200 per year, compared to costs ranging from 
$200 to $1500 for home visiting programs [41]. Yet home visit programs are limited, 
largely because health care payers do not reimburse for them. 
2.5.3. Asthma policy 
Clinical practice guidelines describing quality health care for asthma have been in 
existence for two decades. The National Asthma Education and Prevention Program 
(NAEPP) Guidelines for the Diagnosis and Management of Asthma provide an 
evidence-based treatment regime [14].  They describe four components of good asthma 
management including 1) objective assessment and monitoring, 2) pharmacologic 
therapy, 3) patient education, and 4) environmental control.  There exists a gap 
between what is known to be best practice and what is covered by insurers, required by 
purchasers, and implemented by providers. The American Lung Association published a 
National Asthma Public Policy Agenda in 2009 [43].  They provide a comprehensive 
overview of health-care systems and financing which could impact asthma policy. One 
of the strategies included was to “Provide case management, including home-based 
environmental assessment and remediation, for high-risk patients and those whose 
asthma is not under good control.” 
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The NHLBI Guidelines Implementation Panel Report [44] recommends the development 
of protocols and coverage for in-home environmental trigger reduction supplies and 
services for children and adolescent as appropriate and needed.  Children and youth 
whose asthma is not under control should have comprehensive coverage which covers 
environmental trigger education, environmental interventions such as mattress/pillow 
covers, HEPA air filters, HEPA vacuums, and integrated pest management.  In some 
cases, remediation may be appropriate as well [11, 24]. 
2.6. Employers/Managed Care/Health Insurers 
2.6.1. Background 
Employers expend 2.5 times the amount for patients with asthma compared to patients 
without the disease [5]. Furthermore, in the U.S. 2007, almost a quarter ($4.7 billion) of 
the $19.7 billion spent on  asthma was spent on preventable visits to the hospital; 
another 31% of the expenditures ($6.2 billion) was spent on prescription medications 
[45].  Yet, employers and health insures alike have yet to align employee health benefits 
with the recommended best practices for asthma management [24].  The effect of such 
changes can impact employers and health insurers differently.  Self-insured employers 
which offered expanded benefits for asthma care should incur cost-savings, including 
savings from increased productivity among employees, and incur reduced insurance 
premiums. Employers who purchase health insurance will not realize any direct cost-
savings, but their insurer will from the reduced use of urgent care.  However, such 
employers will  benefit from increased productivity and reduced employee absenteeism 
and increased presenteeism [24].  Such employers can make an evidence based case 
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that premiums should not be increased to cover asthma management, as the service 
will be cost-effective and may generate cost-savings [24].   
Many employers are actually self-insured, and would actually receive the benefits 
themselves.  Further, even when employers are purchasing insurance, a competitive 
insurance market would yield lower premiums in the long-run when cost-beneficial 
programs are adopted. 
2.6.2. Insurance Reimbursement 
There are a number of policy issues related to the implementation of the NAEPP 
guidelines.  From an insurance perspective, major issues remain with insufficient and 
inconsistent insurance benefits, the high costs of prescription medications, the lack of 
reimbursement for educational services and case management, and an unwillingness to 
consider the reduction in environmental exposures.  These concerns contrast a CDC 
review which found that the combination of  minor to moderate environmental 
remediation with an educational component provides good value for the money invested 
based on improvement in symptom free days, savings from medical costs averted, and 
improvement in productivity [11]. 
Some disease management programs are offering some of the asthma best practice 
components, but very few offer home visits for environmental assessments and 
interventions.  This component may be very important for people whose asthma is not 
under control [24].  Also, health care employers and purchasers do not want to make 
changes to their benefits package which may result in increased costs.  
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The fact that managed care organizations have not been keen on providing primarily 
behavioral interventions for disease prevention and health promotion services is a 
longstanding issue [35].  For asthma home visiting and remediation services, initial 
intervention costs are upfront, and in the case of reduced expenditures for asthma, the 
benefits and cost-savings may accrue over months or years. Given the expected 
benefits of reduced urgent care use, reduced absenteeism, and presenteeism, health 
insurance premiums should not increase as a result of investing in managing asthma 
[24]. 
2.6.3. Actions that can impact Health Coverage and Care Practices 
Industry Report Cards can play a significant role on health plans emphasis on providing 
a particular service. The Health Plan Employer Data and Information Set (HEDIS) “is a 
tool used by more than 90 percent of America's health plans to measure performance 
on important dimensions of care and service. Altogether, HEDIS consists of 75 
measures across 8 domains of care. Because so many plans collect HEDIS data, and 
because the measures are so specifically defined, HEDIS makes it possible to compare 
the performance of health plans on an "apples-to-apples" basis [4, 46]. Payers routinely 
provide incentives to insurers who meet certain benchmarks, known as “Pay for 
Performance” programs [4].  If a performance measure is established for a particular 
condition, and it is established as a benchmark, insurers will clamor to increase their 
outcomes in those areas [47].  HEDIS has adult and child core measures, which are 
used by the Centers for Medicare and Medicaid.  Several of those measures pertain to 
asthma care.   
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HEDIS 2013 included the following selected measures on asthma management: 
enrollees had to have experienced continuous enrollment (for the measurement year 
and year prior), and the measures were provided for all enrollees ages 5-64, and by age 
brackets, including children aged 5-11 and 12-18. 
Use of Appropriate Medications for People With Asthma (ASM) The percentage 
of members 5–64 years of age during the measurement year who were identified 
as having persistent asthma and who were appropriately prescribed medication 
during the measurement year. 
Medication Management for People With Asthma (MMA) Two rates, (1) the 
percentage of members who remained on an asthma controller medication for at 
least 50% of their treatment period; (2) the percentage of members who 
remained on an asthma controller medication for at least 75% of their treatment 
period. 
 
The State of Michigan Medical Services Administration auto-assigns about 20% of 
enrollees to insurance plans which are high-performing.  An algorithm determines the 
number of assignees per plan based on how they do on quality metrics.  If a health plan 
wants to focus on a metric, from a business perspective the best reward would be to 
focus on the metric which determines the auto-assignment of beneficiaries [48].  The 
metrics used change every year, on a quarterly basis.  A managed care provider can be 
downgraded for a lack of effective prevention services, which may result in declining 
enrollments [35].   
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Consolidation of health care may have a positive impact on the provision of preventative 
services. A health care plan that dominates a particular marketplace, or which owns 
multiple plans in a particular catchment area, will have an incentive to provide 
preventative services, as they are more likely to hold on to their enrollees for significant 
periods of time [35]. 
Provision or non-provision of services also impacts enrollment in health plans.  If there 
is demand for a particular service, and the health plan does not cover it, they may lose 
members to a plan that does. Therefore it may be worth the expense to provide the 
service, regardless of the cost-effectiveness of the intervention [35]. 
Enrollee and provider demand for services is another determinant in health coverage. 
Beneficiaries and providers alike demand high cost crisis management interventions 
that are not necessarily cost-effective.  However, there is not the same clamor for 
preventative measures with benefits in the long-term. 
Government mandates are a final determinant of coverage.  Governing entities, such as 
State insurance commissioners, have the authority to require coverage of interventions.  
This would address the problem of an organization bearing the cost of coverage, whilst 
another organization accrued the benefits.  
2.6.3.1. New Strategies to pay for Preventative Services 
The historical fee for service health care model embodied by the U.S. healthcare 
system lacks incentives for providers and insurers to invest in prevention [49].  A chorus 
of providers, practitioners, and community health planners are investigation new 
financing approaches to pay for preventative services on a population level scale, 
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starting at the local level.  The following outlines some of the predominant ideas which 
are being proposed and tested. 
Health Impact Bonds propose raising capital from private investors to target community 
prevention initiatives through evidence –based clinical and community care, and 
leveraging future health care cost savings to pay for prevention today. Savings from 
such initiatives are returned to investors, and are re-invested, creating an ongoing 
system of better health and lower costs. Such a bond is being implemented in Fresno, 
California, by the University of California, Berkeley, and a health impact investing firm, 
Collective Health, targeting the incidence and severity of asthma by investing in home-
based remediation of environmental conditions in homes of 200 local children with 
moderate to severe asthma [49, 50]. The California Endowment, a private health 
foundation, is investing $1.1 million in the project [50], and the intervention is estimated 
to generate a net savings of $4.5 million, and a return of investment of $1.69 for every 
dollar spent [49].  If successful, investors will be repaid by the insurers through a portion 
of the savings realized by lowered emergency department visits, hospitalizations, and 
post intervention treatment costs. 
Wellness Trusts are funding pools typically funded by taxing a levy on insurers and 
hospitals, in order to support the health and wellness interventions to improve targeted 
populations. Many of the funded initiatives from such trusts carry out prevention 
initiatives which are community-based, and which address preventable health 
conditions, increasing healthy behaviors, and reducing health disparities. This funding 
mechanism disperses the benefit of the intervention to all members of the targeted 
population, reducing insurer reluctance to pay for a service for an enrollee which they 
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may ‘lose’, as they may as likely ‘gain’ a member who will have benefited from the 
investment [49]. 
Community Benefits requirements were enacted under legislation passed in 1994 which 
required hospitals, as a condition of their tax-exempt status, to provide “community 
benefits in the public interest” [49].  About 2,900 or 60% of hospitals nationwide are 
non-profit, and the tax-exemption was valued at $12.6 billion dollars annually [51]. New 
requirements under the Affordable Care Act (ACA) require tax-exempt hospitals  to do 
community health needs assessments and improvement plans every three years, and 
adopt implementation plans which address the community’s health needs [49, 51]. 
Effective in 2012, community building activities, which focus on upstream 
environmental, social, and economic factors, are eligible to be counted as community 
benefit expenditures, providing a new resource to fund prevention activities [52].  The 
IRS has also asked hospitals to track such expenditures, defined as support for 
“physical improvement and housing, economic development, community support, 
environmental improvements, leadership development for community members, 
coalition building, and community health improvement advocacy, and workforce 
development” [49, 52].  These activities are understood to benefit the population’s 
health without the provision of medical care. 
A recent literature review of cost-effective analyses indicates that environmental 
interventions are generally more cost-effective than clinical interventions or non-clinical, 
person-directed interventions [53].  This may encourage purchasers of health care, as 
well as other payers, to leverage new payment strategies to pay for preventative 
services. 
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Chapter 3 
Conceptual Model and Study Hypothesis 
3.1.  Conceptual Model 
The purpose of the project is to conduct a return on investment (ROI) or cost-benefit 
analysis of the second round of a program implemented in Lansing, Michigan to study 
the relationship between the Healthy Homes University II (HHU II) Program 
interventions and utilization of emergency department, hospitalization, urgent care, 
physician/clinic utilization, and prescription use due to acute asthma events.  The 
project will consider the health benefits and cost-effectiveness of asthma programs that 
supplement quality clinical care with asthma education and environmental interventions 
in the home.   
Best practices have been identified by NHBLI [9]. If cost-effectiveness of the 
implementation can be demonstrated, a business case of investing in comprehensive 
asthma management programs which include comprehensive asthma education and in-
home environmental interventions could be made to health care payers and purchasers.  
Gaps in insurance reimbursement and policy implications for payer organizations will be 
explored.  If health insurers routinely reimbursed for these services and supplies, they 
could become standard components of comprehensive asthma management. 
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The Program will be evaluated using a quasi-experimental study in which changes in 
Medicaid claims for asthma among the intervention group are compared to changes 
among a control group. 
3.2. Hypothesis 
The hypothesis is that children with moderate to severe asthma who receive asthma 
education and environmental interventions in the home will have lower total medical 
costs related to lowered utilization of outpatient, emergency department, hospitalization, 
and use of rescue medications due to acute asthma events than children in a matched 
control group which do not receive any interventions. 
Exploratory research questions that will be considered include: 
1. Are asthma education and environmental interventions in the home associated 
with lower utilization of asthma-related outpatient services? 
2. Are asthma education and environmental interventions in the home associated 
with lower costs of asthma-related outpatient services? 
3. Are asthma education and environmental interventions in the home associated 
with lower utilization of asthma-related Emergency Department (ED) services? 
4. Are asthma education and environmental interventions in the home is associated 
with lower costs of asthma-related Emergency Department (ED) services? 
5. Are asthma education and environmental interventions in the home associated 
with lower utilization of asthma-related hospitalizations? 
6. Are asthma education and environmental interventions in the home associated 
with lower costs of asthma-related hospitalizations? 
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7. Are asthma education and environmental interventions in the home associated 
with lower utilization of asthma-related rescue medications? 
8. Are asthma education and environmental interventions in the home associated 
with lower costs of asthma-related rescue medications? 
9. Are asthma education and environmental interventions in the home cost-
effective? Do they result in a cost-savings of asthma –related outpatient, 
emergency department, inpatient, and prescription services, when taking into 
account the cost of Healthy Homes’ interventions? 
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Chapter 4 
The Intervention 
4.1. Introduction 
The Healthy Homes II project was implemented from December 15, 2008 through June 
14, 2012, and was an $875,000 award from HUD to the Michigan Department of 
Community Health, Health Homes Section.  In addition $144,792 in product carry-over 
from previous awards, and money collected by the Healthy Homes Section from fines 
and fees collected were spent on the project.  Program match funding of $170,916 were 
comprised of Health Michigan funds ($36,439), Lead-Safe Housing Program funds 
($88,246) and other MDCH program contributions ($44,231).  An additional $122,412 
was leveraged funds provided by local partnering organizations and product suppliers.  
Therefore, an estimated $1,313,120 was spent on the project. 
4.2.  Description of the HHU II Project Population 
Two hundred and fifty participants were recruited to participate in the study, 240 of them 
from Greater Lansing, MI, and ten from Flint, MI.  For the purposes of the evaluation, 
only the Greater Lansing participants were included in the evaluation.  All 240 
participants received a HHU II Baseline Visit, and were provided with the project 
protocol.  The model included a minimum of four site visits for enrolled families that 
included a joint health education/home assessment site visit, allergen sampling 
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collection and analysis for 50 of the participant homes, Basic and Custom asthma 
trigger reduction and injury product installation to address identified health and safety 
risks in the home, and follow up calls and/or visits.  The HHU Program Recruitment and 
Program Flow Diagram (attrition chart) is in Chapter 5, Table 5.1. 
4.2.1. Baseline Demographic Characteristics of the HHU II Project 
Population 
Two hundred and forty participants participated in the project. Applications were 
prioritized based upon a score matrix. This matrix consisted of 14 child specific 
questions and 11 housing related questions. Points were awarded based on how each 
question was answered. High scores were matched with units that housed children 
under six years old, had an asthma diagnosis and/or symptomology, based on the 
location and condition of the home, and the presence of multiple children living in the 
unit. Those applications which scored the highest were placed at a higher priority for 
completion. 
At the conclusion of the project, and for the purpose of this cost-benefit analysis, all 
participants were matched to the Medicaid database to determine which participants 
were continually enrolled in Medicaid, 12 months prior to the intervention, during the 
intervention month, and 12 months post intervention, for a total of 25 continuous months 
of Medicaid enrollment.  Forty participants met this criterion and were deemed to be “in 
the study”.  The remaining 200 were deemed to “not be in the cost-benefit study.”  Table 
4.1 provides a description and comparison of the two groups.  None of the differences 
between any of the variables described were statistically significant. 
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The majority of the participants were male (62.5%), and the remainder female (37.5%). 
Just under half of the participants were under the age of six (45.8%), and 54.2% were 
between the ages of six and eighteen (54.2%).  The majority of participants were white 
(49.6%), followed by black (30%) and other races (20%).  Hispanics represented 13.8% 
of the study population.  
The majority of the caregivers reported having some college, 46.3%, followed by high 
school graduates, 22.1%, those with less than high school, 16.7%, and college 
graduates at 15%. 
Virtually all of the participants reported having health coverage (98.8%).  Of those, 
almost 14% were covered by a private insurer, and the vast majority, 75.4%, was 
covered by public insurance, or Medicaid. Ten percent reported other health insurance 
coverage.  
Almost thirty three percent of the individuals lived in pre-1940 housing, with a similar 
amount in 1960-1977 housing, twenty percent in post 1978 housing, and almost 14% in 
1940-1959 housing.  The majority of participants lived in rental housing, 61.3%, and 
almost 38.8% lived in owner occupied housing.   
Finally, a majority, 56.3% of participants received basic and custom interventions, while 
only 43.8% received baseline interventions only. 
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Table 4.1: Demographics of HHU II Participants, by Medicaid Study participation 
  
Received HHU 2 Baseline Visit     
Medicaid Study 
(n=40) 
Not in Study 
(n=200) Total (n=240) 
No. % No. % No. % 
Gender 
Male 27 67.5% 123 61.5% 150 62.5% 
Female 13 32.5% 77 38.5% 90 37.5% 
Age at Baseline (years) 
< 6 21 52.5% 89 44.5% 110 45.8% 
6-18 19 47.5% 111 55.5% 130 54.2% 
Race 
White 22 55.0% 97 48.5% 119 49.6% 
Black 9 22.5% 63 31.5% 72 30.0% 
Other 9 22.5% 39 19.5% 48 20.0% 
Unknown 0 0.0% 1 0.5% 1 0.4% 
Hispanic 
Yes 7 17.5% 26 13.0% 33 13.8% 
No 33 82.5% 174 87.0% 207 86.3% 
Age of Housing 
Pre 1940 14 35.0% 64 32.0% 78 32.5% 
1940-1959 5 12.5% 28 14.0% 33 13.8% 
1960-1977 16 40.0% 61 30.5% 77 32.1% 
Post 1978 5 12.5% 44 22.0% 49 20.4% 
Unknown 0 0.0% 3 1.5% 3 1.3% 
Healthcare coverage 
Yes 40 100.0% 197 98.5% 237 98.8% 
No 0 0.0% 3 1.5% 3 1.3% 
Rental occupancy 
Owner-Occupied 9 22.5% 84 42.0% 93 38.8% 
Rental 31 77.5% 116 58.0% 147 61.3% 
Received Custom or Not 
Received Custom 22 55.0% 113 56.5% 135 56.3% 
No  Custom 18 45.0% 87 43.5% 105 43.8% 
Caregiver Education 
< HS 5 12.5% 35 17.5% 40 16.7% 
HS Grad 10 25.0% 43 21.5% 53 22.1% 
Some College 20 50.0% 91 45.5% 111 46.3% 
College Grad 5 12.5% 31 15.5% 36 15.0% 
Healthcare Source 
Private Employer 6 15.0% 27 13.5% 33 13.8% 
Public 32 80.0% 149 74.5% 181 75.4% 
Other 2 5.0% 23 11.5% 25 10.4% 
Missing 0 0.0% 1 0.5% 1 0.4% 
 
4.3. Project costs 
Project costs can be divided into 5 categories.  Additionally, project costs can be divided 
into costs which would be required to implement a similar program by a private entity, 
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with reduced components, which will be deemed “MARGINAL”, “DIRECT”, and “FULL” 
for evaluation purposes, many of which would not be necessary in the private sector. 
These components are described in detail in section 4.3. 
4.3.1. Personnel 
Personnel costs were the largest expense.  Over the course of the project, $269,908 
was spent on the HHU II Program Manager (included in the DIRECT and FULL costs, 
and $252,925 on the Family Services Coordinator (Included in the MARGINAL, 
DIRECT, and FULL cost calculations. 
An additional $61,131 was spent on an epidemiologist, who performed statistical 
analysis of project survey tools that were used to document health outcome 
measurements.  The epidemiologist also performed quality control and quality 
assurance of survey tools and data management. Additionally, $14,196 was expended 
for a health analyst to analyze participating family Medicaid records in order for HHU to 
build surveillance systems of the asthmatic populations to track changes in incidence 
rates, monitor adherence to treatment protocols, and generate cost justification 
analyses.  These latter costs would not be necessary for implementation in the private 
sector and will be excluded in the “MARGINAL” and “DIRECT” cost calculations. 
4.3.2. Travel 
Travel expenses included the conference travel for project staff to Washington, D.C. (15 
trips), at a cost of $18,919.  This travel included HUD Grantee Orientation and other 
HUD-sponsored conferences that benefit staff professional development and 
performance of the Healthy Homes University Program. Additionally, $8,922 was spent 
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on the mileage and parking costs to house the project vehicle. Only these costs would 
be necessary for implementation in the private sector and will be included in the 
“MARGINAL” analysis.   
4.3.3. Supplies and materials 
This item includes consumable supplies (general office supplies, partnership meeting 
supplies, phone charges , healthy homes course manuals,  allergy testing supplies), 
which totaled $19,719 of the supply budget. This budget category included phone 
service for arranging appointments with participating families and to conduct follow-up 
calls with families between home visits.  The project provided an in-depth manual (275 
manuals at $20/each) to participating families with resource materials that could be 
consulted for all aspects of the HHU Program’s Healthy Homes approach.  
Additionally, Allergen testing was performed on fifty (50) units, which was 20% of the 
250 total units.   This included sampling and analysis by Johns Hopkins School of 
Medicine Reference Laboratory for dust mites (Dermatophagoides farinae), 
cockroaches (Bla g I and II), and mouse urinary protein (as needed).  The total cost of 
allergen sampling was $8,459.  Samples were collected in food preparation and eating 
areas and key indicator child living and sleeping areas.  Each home received sampling 
at baseline, 6 month and 12 month intervals.   
The costs of the general office supplies and allergen testing were not counted in the 
calculation of MARGINAL and DIRECT costs. 
Supplies also included non-consumable materials, which totaled $166,946 of the 
supplies budget.  Non-consumable materials included the items outlined in Table 4.2. 
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These included the basic and custom costs for the 240 homes in the HHUII Lansing 
location, and the 10 homes in the HHUII Flint location. They were included in the 
MARGINAL, DIRECT, and FULL cost calculations. 
The Basic Intervention services (average cost $449/unit)  consisted of installing the 
following products, based on the identified needs of the individual home and family:  9-
volt batteries ($1.28), D batteries ($0.69), bath mat ($11.68), cabinet safety locks 
($2.19), cabinet slide locks ($2.52), carbon filter for air purifier ($19.00), CO detector 
($15.50), caulk ($1.80), door mat ($6.30), fan ($9.00), fire extinguisher ($16.20), first aid 
kit ($5.39), flashlights ($3.60/2pk), foam crack sealant ($2.19), food container- large 
($5.40), food containers - small ($18.00/30ct), furnace filter ($3.60), gun trigger locks 
($0.00 as they were leveraged from a partner program), HEPA room air purifier 
($100.00), HEPA vacuum ($129.99), HEPA vacuum bags ($3.48).hypoallergenic 
mattress covers (twin - $27.92, full - $35.90, queen - $40.15, king - $51.68), 
hypoallergenic pillow cover ($4.69), mice baits ($3.60/8pk), nightlights ($1.80), outlet 
covers ($2.40/30ct), poison control magnet ($0.00), pull-cord wind-ups ($1.80/2pk), 
roach baits ($6.36/12pk), safety gate ($9.00), shower curtain ($2.10), step stool ($4.50), 
smoke alarm ($5.00), thermometer ($3.60), trash can with lid ($9.90). Included in these 
prices were a green cleaning kit to reduce in home chemicals. The kit included the 
following items: bucket ($1.68), disposable gloves ($7.74/100ct), mop handle ($7.17) 
and mop head refills ($9.68/3pk) or Swiffer handle ($8.08) and refills ($6.72) depending 
on flooring surfaces in home, shop towels in a box ($7.20), spray bottle ($1.78), 
SoftSoap ($1.37), Simple Green ($5.04), and Murphy’s Oil Soap ($4.29). 
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The Custom Intervention Products (average cost $391/unit)   were installed based on 
need and program compliance of the family. Included products that were installed were: 
window air conditioning units for eligible housing to be located in subject child’s 
bedroom (average cost $100.00); twin mattress, box spring, and frame ($295.00); full 
mattress, box spring, and frame ($374.00); dehumidifiers for homes with bedrooms at 
ground or basement levels (average cost $160.00); and dryer vent repair (average cost 
$30.00). 
 
 
Table 4.2: Basic and custom intervention products and services 
Basic - Asthma Related Products Basic - Safety Related Products 
 HEPA vacuum 
HEPA room filters 
Trash can with secure cover 
Food containers with securing lids 
Smoking cessation kit 
Green cleaning supplies 
Pillow and mattress covers 
IPM traps and baits 
Foam crack sealant 
 Caulk 
Shower curtain 
Low allergen furnace filters 
Door mats 
Fan 
Outlet safety plugs 
 Carbon monoxide and smoke detectors 
 Cabinet safety locks 
 Skid proof bathtub mats 
 Fire extinguisher 
 Gun trigger locks 
 Mercury-free thermometers 
 Poison Control Stickers and First aid kits 
 Child safety gate 
 Mini blind cord wind-ups 
 Flashlights and nightlights 
 Step stool 
 Radon test kits 
Custom Products Custom Services 
Beds and pillows  Carpet removal and floor replacement 
Surge protectors  Integrated pest management services 
Dehumidifiers Slope/yard grading 
Window air conditioning unit Electrical improvements  
Dryer vent/extenders Garbage removal 
Gutter extenders Moisture control (ventilation, gutter 
installation, plumbing repair, roof repair) 
 
4.3.4.  Consultants 
A total of 6 individuals were trained to perform product installation and assessments for 
healthy homes interventions.  Two Technical Assistants (TA's) were hired and trained to 
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install the HHU II products given to the families on the Baseline Site Visits. The HHU II 
Program Manager, Assistant Field Coordinator and two CDC Apprentices were also 
trained to administer health questionnaires and education, install basic intervention 
products, in the event a technical assistant could not attend the scheduled site visit.  
Additionally, lead paint worker and supervisor educational stipend funding ($500) was 
provided to five (5) low – moderate-income individuals within the target community to 
install products and services.   
A policy and procedure document was created to delineate the responsibilities and 
duties of the TA’s.  In summary, the responsibilities included; performing a visual 
assessment of all interior and exterior components of the structure, yard and 
outbuildings for asthma triggers and injury hazards; installation of the intervention 
products; recording the type, number, and location of each product installed on the 
room-by-room checklist; walking through the home to identify products, show the family 
how to use and maintain products and educate the family on products installed within 
the home.  The total spent on product installation and assessments for healthy homes 
interventions was $50,675.  This amount was included in MARGINAL, DIRECT, and 
FULL costs and calculations. 
At the baseline site visit the families completed the baseline survey; received education 
regarding home asthma triggers and injury control based on answers to the 
questionnaire; and basic health and safety products were installed within the home.  
The baseline questionnaire contained questions related to the demographics, family 
history, symptomatology, quality of life, medical visit frequency, medication usage, 
asthma knowledge and home environment.  The visual inspection identified the 
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environmental, health and safety risks in the unit.  It also provided the program with 
information to determine the priority and level of intervention work needed in a unit.  The 
program staff provided hands-on education regarding asthma triggers, home safety and 
basic home maintenance to every family.  Each family received the HHU II Course 
Manual which included topics, such as; asthma medications, asthma triggers, asthma 
action plan, nutrition, smoking cessation resources, home safety, HEPA vacuum and 
room filters, pesticides, green cleaning products, air scents, asbestos, radon, lead-
based paint and local resources.  Every family received the installation of the basic 
products and a subset of families received various custom products and services.  Both 
are outlined in Table 4.2.  Baseline and custom products were included in the 
MARGINAL, DIRECT, and FULL cost calculations. 
4.3.5. Other Costs 
Financial Administrative Services costs totaled $57,000, and were for the administration 
of financial services by the Michigan Department of Community Health offices of finance 
and budget for providing services for LOCC’s draw down, purchasing of supplies and 
overseeing contracts and grant administration.  
Environmental Review Public Notices funding in 3 local newspapers at a total cost of 
$1,500 was expended to meet HUD’s Environmental Review Procedures. $400 was 
spent on the Flint site and $1000 to support neighborhood coalitions. 
The part time epidemiologist had indirect costs of $4,780. 
The Program Manager and Family Services Coordinator were retained via contract with 
a non-profit local public health institute that offered flexibility and innovation to the 
project.  This contract charged $5.671 in computer costs, and an indirect of $77,624 
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over the three years of the project. These ‘other’ costs were only counted in the ‘FULL’ 
costs calculations. 
4.3.6. Total Costs 
Project implementation costs totaled $1,313,120.  Personnel costs were the largest 
expense representing 47% of the total cost of the project.  This was followed by 
leveraged/match funds at  22%, supplies/materials at 14%, direct costs at 6%, other 
indirect costs at 5%, consultants at 4%, and travel at 2%, representing the actual 
implementation costs.  
4.4. Cost Considerations 
One way to consider real-world implementation costs, is to consider what the “Marginal” 
components and marginal costs of a basic intervention program would include; what a 
more comprehensive program including ‘Direct” costs would include; and finally, the 
costs of the implementation of the “Full” project as was implementations of the “Healthy 
Homes University” II project. Of course, each participant in HHU II received a different 
amount of interventions customized based on their needs, so the “fixed” program costs 
per person are $1250 for the marginal costs, $2922 for the direct costs, and $4003 for 
the full costs, illustrated in Table 4.3. 
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Table 4.3: Elements:  Marginal, Direct, & Full Project Comparisons 
MARGINAL Costs Description Marg_Costs 
Basic remediation actual 
Custom Remediation actual 
Technical Assistants to install Products $50,675 
Family Services Coordinator $252,925 
Basic Transportation $8,922 
TOTAL fixed MARGINAL costs per person $1,250 
  
DIRECT Costs Description Direct_Costs 
Basic remediation actual 
Custom Remediation actual 
Custom Remediation by Partner actual 
TOTAL fixed MARGINAL costs per person $1,250 
Technical Assistants to install Products ($50,675)   
Family Services Coordinator ($252,925)   
Basic Transportation($8922)   
addt'l Direct Costs average cost per person $1,671 
Leveraged 65,293 
Match 82,670 
Program Manager 269,908 
TOTAL fixed DIRECT costs per person $2,922 
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Once the actual remediation costs are added, Figure 4.1, Figure 4.2 and Figure 4.3 
show the average marginal ($1,918), direct ($4,171), and full costs ($5,252) per 
participant in the project. 
 
TABLE 4.3 (Cont’d) 
Elements:  Marginal, Direct, & Full Project Comparisons 
 
FULL Costs Description Full_Costs 
Basic remediation actual 
Custom Remediation actual 
Custom Remediation by Partner actual 
Marginal Staff average cost per person $1,250 
Technical Assistants to install Products 
($50,675)   
Family Services Coordinator ($252,925)   
Basic Transportation($8922)   
Direct Costs average cost per person $1,671 
Leveraged ($65,293)   
Match($82,670)   
Program Manager($269,908)   
addt'l FULL Costs average cost per person 1,082 
Epidemiologist  $35,959  
Epidemiologist Fringe $25,171  
Transportation-HUD  $18,919  
Supplies  $19,719  
Allergy testing  $8,459  
Data Analyst  $14,196  
Flint  $400  
Neighborhood Coalition $1,000  
Environmental Review Notices  $1,500  
RMC -Financial Services MDCH  $57,000  
Epidemiologist Indirect  $4,780  
MPHI  $77,642  
Computers MPHI $5,671  
TOTAL fixed FULL costs  per person $4,003 
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Figure 4.1: MARGINAL Costs 
 
Marginal Staff $303,600   Supplies/Materials $166,946 
Technical Assistants $50,675   Basic $109,635 
Family Services Coord $252,925   Custom $57,311 
          
Travel $8,922   Total Cost $479,468 
Basic Transportation $8,922   Average cost per participant $1,918 
 
Marginal Staff
63%
Travel
2%
Supplies/Materials
35%
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Figure 4.2: DIRECT Costs 
 
Marginal Staff $303,600   Additional Direct Costs $563,237 
Technical Assistants $50,675   Leveraged-custom partner $56,489 
Family Services Coord $252,925   Leveraged -other $65,923 
      Match-custom partner $88,246 
Travel $8,922   Match-other custom products $36,439 
Basic Transportation $8,922   Match -other partner $46,232 
      Program Manager $269,908 
Supplies/Materials $166,946       
Basic $109,635   Total Cost $1,042,705 
Custom $57,311   Average cost per participant $4,171 
 
 
Marginal Staff
29%
Travel
1%Additional Direct 
Costs
54%
Supplies/Materials
16%
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Figure 4.3: FULL Costs 
 
Marginal Staff
23%
Travel
1%
Supplies/Materials
13%
Additional Direct 
Costs
43%
Additional Full 
Costs
20%
Marginal Staff $303,600   Additional Full Costs $270,416 
Technical Assistants $50,675   Epidemiologist $35,959 
Family Services Coord $252,925   Epidemiologist Fringe $25,171 
      Transportation-HUD  $18,919 
Travel $8,922   Supplies  $19,719 
Basic Transportation $8,922   Allergen Testing  $8,459 
    Data Analyst  $14,196 
Supplies/Materials $166,946   Flint  $400 
Basic $109,635   Neighborhood Coalition  $1,000 
Custom $57,311   Environmental Review Notices  $1,500 
    RMC -Financial Services MDCH  $57,000 
Additional Direct Costs $563,237   Epidemiologist Indirect $4,780 
Leveraged-remediation $56,489   MPHI  $77,642 
Leveraged -other $65,923   Computers MPHI  $5,671 
Match-remediation $88,246     
Match-other custom products $36,439     
Match -other partner $46,232   Total Cost $1,313,121 
Program Manager $269,908   Average cost per participant $5,252 
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4.4.1. Comparing Basic and Custom Interventions 
To ensure cost-effective methods to address multiple housing related health and safety 
hazards within the participating units, the installation of Basic Intervention products were 
based on the results of the visual assessment performed by the Program Manager or 
Family Services Coordinator. Each unit was provided the Basic and Custom products 
specifically to control health and safety hazards in the unit. However, for most product 
installations, work specifications were not required. Technical Assistants installed all 
products appropriate for each unit. Some Custom Interventions involving repairs and 
maintenance may have required work specifications. In those instances, the HHU 
Program adhered to the Michigan Building Code and local building code regulations. 
For services not addressed in the Code, the Program Manager consulted with the 
Healthy Homes Section Building Rehabilitation Specialist to develop appropriate 
specifications. Specifications and contractor bid procedures were modeled after the 
Lead-Safe Homes program. 
4.4.2. Basic and Custom Products and Services Costs for HHU II 
Project 
The mean cost for the basic intervention was $456, with a range between $268 and 
$723.  The mean custom cost was $230, with a range between $252 and $4527. The 
mean cost for those who received basic and custom products was $687, with a range 
between $252 and $5108 (Table 4.4). 
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Table 4.4: Costs of Basic, Custom, and Total (Basic and Custom) Intervention 
Products and Services for all HHU II participants (n=240) 
      
 N Min Max Mean S.D. 
Basic 240 $268 $723 $456 $77 
Custom 240 $252 $4,527 $230 $479 
Basic and Custom 240 $252 $5,108 $687 $510 
 
 
 
      
The mean basic costs were similar for the study and non-study project participants, and 
were not significantly different (Table 4.5). 
 
 
Table 4.5: Costs of Basic Intervention Products and Services 
Study (n=40) versus Not in Study (n=200) 
              
  N Min Max Mean Range S.D. 
Not in Study 200 $268 $723 $456 $455 $77 
In Study 40 $252 $602 $460 $350 $81 
 
 
The mean custom costs were similar for the study and non-study project participants, 
and were not significantly different (Table 4.6). 
 
 
Table 4.6: Costs of Custom Intervention Products and Services 
Study (n=40) versus Not in Study (n=200) 
              
  N Min Max Mean Range S.D. 
Not in Study 200 $0 $4,527 $242 $4,527 $516 
In Study 40 $0 $726 $172 $726 $217 
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The mean total basic and custom costs was comparable between the two groups, the 
study group and the not in study group and were not significantly different (Table 4.7). 
 
 
Table 4.7: Costs of Basic and Custom Intervention Products and Services 
Study (n=40) versus Not in Study (n=200) 
              
  N Min Max Mean Range S.D. 
Not in Study 200 $268 $5,108 $698 $4,840 $547 
In Study 40 $252 $1,190 $632 $938 $254 
 
 
 
 
The mean total basic and custom costs, including partner remediation costs, was 
comparable between the two groups, the study group and the not in study group and 
were not significantly different (Table 4.8). 
 
 
Table 4.8: Costs of Basic and Custom Intervention Products and Services including Partner 
Remediation Costs 
Study (n=40) versus Not in Study (n=200) 
 
  N Min Max Mean Range S.D. 
Not in Study 200 $268 $21,944 $1,269 $21,676 $2,715 
In Study 40 $252 $8,539 $829 $8,287 $1,276 
 
       
 
4.4.3. Custom Intervention Products and Services 
The majority of the custom intervention products were bed related products; mattresses 
(14.7%), bed frames (12.6%), and box springs (11.6%), for a total of 38.9% of all 
custom products.  These were followed by air conditioning units (12.4%), pillows 
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(11.9%), and dehumidifiers (11.1%).  Combined, these products represented 74.3% of 
all custom products provided (Table 4.9). 
Table 4.9: Custom intervention products and services 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
 
AC 48 12.4 12.4 12.4 
Bath sink plumb 1 0.3 0.3 12.6 
Bathroom moisture control 1 0.3 0.3 12.9 
Bathtub surrounds 1 0.3 0.3 13.1 
Bed Frame 49 12.6 12.6 25.8 
Box Spring 45 11.6 11.6 37.4 
Carbon Pre Filter 1 0.3 0.3 37.6 
Carpet Removal-SC Bed 1 0.3 0.3 37.9 
Change Order 1 0.3 0.3 38.1 
Dehumidifier 43 11.1 11.1 49.2 
Dryer Vent Hookup/Extension 16 4.1 4.1 53.4 
Fan install 1 0.3 0.3 53.6 
Flooring Replacement 2 0.5 0.5 54.1 
Gutter Extenders 19 4.9 4.9 59 
Gutter maintenance 1 0.3 0.3 59.3 
HEPA Filter and/or  Carbon Filter 12 3.1 3.1 62.4 
HVAC SVC 1 0.3 0.3 62.6 
IPM 3 0.8 0.8 63.4 
Kichen Repair Ceiling Repair Carpet 
Removal 1 0.3 0.3 63.7 
landscaping 1 0.3 0.3 63.9 
Mattress 57 14.7 14.7 78.6 
Mattress Cover 7 1.8 1.8 80.4 
Moisture Reduction 2 0.5 0.5 80.9 
Outlets 1 0.3 0.3 81.2 
Painting 1 0.3 0.3 81.4 
Pillows 46 11.9 11.9 93.3 
Plumbing 1 0.3 0.3 93.6 
Roof Repair 1 0.3 0.3 93.8 
Safety rails for bed 1 0.3 0.3 94.1 
Sash lock 1 0.3 0.3 94.3 
steps/walk replacement 1 0.3 0.3 94.6 
Surge Protector 16 4.1 4.1 98.7 
Totes 3 0.8 0.8 99.5 
Tub wrap 1 0.3 0.3 99.7 
Vacuum Maintenance 1 0.3 0.3 100 
Total 388 100 100   
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Chapter 5 
Methodology and Research Design 
5.1. Study Design 
The study is a case-control study of the cost implications of an Asthma Healthy Homes 
Intervention Program. 
The primary outcomes of interest are medical costs, defined as the total expenditures 
on healthcare claims during the 12 month period following the intervention.  Average 
costs for this period were assessed for asthma related: outpatient office and clinic visits, 
other outpatient services, emergency department visits, inpatient stays, and outpatient 
prescription drug expenditures, and are compared with a 12 month period prior to the 
intervention. Healthcare utilization was also compared for each of these categories. 
Study participants were children less than 18 years of age at the end of the observation 
period (i.e., 13 months post Baseline visit); Family Income < 80% of Area Median 
Income; selected among a sampling pool of those continuously enrolled in Medicaid for 
a 25 month period between March 2008 and January 2012 & had either one ED visit or 
one hospitalization due to asthma during the first 12 months of that 25 month period.  
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Data for cases and controls come from Michigan Medicaid claims data and were 
obtained from the Community Health Automated Medicaid Processing System 
(CHAMPS). The time period of Medicaid claims data is March 1, 2008 –December 31, 
2012. The database contains information on the enrollment, as well as medical 
(outpatient, inpatient, emergency department care, physician office visits) and pharmacy 
claims.  
CHAMPS was used to identify and characterize individuals eligible to serve as the 
control study group, and were pulled from comparable populations in Kalamazoo and 
Jackson, Michigan.  Medicaid claims data was matched to program participants and 
controls and downloaded into a database. 
The intervention group comprised of participants in a US Department of Housing and 
Urban Development (HUD) project, Healthy Homes University (HHU II) which operated 
from December of 2008 through December of 2011 (36 months) In Ingham, County, MI 
and some surrounding zip codes.  
The monetary program costs which covered the complete period of the HHU II grant 
period were obtained, as well as the basic intervention costs and custom intervention 
subtotal costs for each subject in the intervention group, for the period of November 1, 
2008 - November 31, 2011. 
5.2. Identification of Intervention and Control Populations 
Controls were selected from Kalamazoo and Jackson Counties, one from each county 
for each of the 40 intervention group members. To ensure that the same time periods 
were included by both intervention and study groups, controls were selected for each of 
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the 25 month timeframes experienced by the intervention group. For example, if an 
intervention group member had their Baseline Visit in January 2010, then one control 
from Kalamazoo and one control from Jackson was selected for which the 25 month 
timeframe was January 2009 – January 2011. As with the intervention group, to qualify 
as a control, the person had to have had either an ED visit or hospitalization with a 
primary diagnosis of asthma during the 12 month “Pre” period. 
5.2.1. Intervention Population:  HHU II Program participants were selected 
using the following criteria: 
Age <18 years of age at the end of the observation period (i.e., 13 months post Baseline 
visit); Residents of Ingham County, MI and zip codes 48906, 48911, and 48917 of 
Eaton County and 48906 of Clinton County; Family Income < 80% of Area Median 
Income. Each intervention group member had a 25 month Medicaid study period. “Base 
Month/Year” was the month/year in which the intervention occurred. The “Pre” period 
was the 12 months prior to the “Base Month/Year.” The “Post” period was the 12 
months following the “Base Month/Year”. To qualify as being an intervention group 
member for the purposes of the Medicaid analysis, the person had to be continuously 
enrolled in Medicaid over this 25 month period and had to have had either an ED visit or 
a hospitalization with a primary diagnosis of asthma during the 12 month “Pre” period. 
5.2.2. Control Group: 
Age <18 years of age at the end of the observation period; selected among a sampling 
pool of those continuously enrolled in Medicaid for a 25 month period between March 
2008 and January 2012. Controls were selected from Kalamazoo and Jackson 
Counties, which did not have asthma intervention programs such as HHU; one from 
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each county for each of the 40 intervention group members. Because asthma 
exacerbation is correlated with time of year, controls were frequency matched by the 25 
month timeframe of the intervention group (12 months pre-intervention month, the 
intervention month, 12 months post-intervention month). For example, if an intervention 
group member had their Baseline Visit in January 2010, then one control from 
Kalamazoo and one control from Jackson was selected for which the 25 month 
timeframe was January 2009 – January 2011. As with the intervention group, to qualify 
as a control, the person had to have had either an ED visit or hospitalization with a 
primary diagnosis of asthma during the 12 month “Pre” period. 
5.3.  Participant Flow Diagram and Attrition table 
The program recruitment and participant flow diagram for the project is illustrated in 
Table 5.1. The data entry was completed, ie program application and risk assessment 
pre/post results were entered into the database.  Data quality assurance was 
completed, as data points and sources of data were re-entered and verified by internal 
and external peer review.  
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180 HH received 6-Month Home Visit 
(156:  Baseline, 3 and 6-Month Home Visits 
24: Baseline, but no 3-Month) 
35 HH discontinued 
Program 
195 HH received 3-Month Home Visit 
21 HH discontinued 
Program 
240 HH in Lansing received the Baseline 
Intervention  
250 HH received the Baseline Intervention  10 HH for Flint pilot 
268 Program applications received and 
enrolled in Program 
18 HH opted out or moved 
from target area 
1,048 fliers returned by households 
18,902 fliers distributed announcing the Program 
40 HH have continuous 25 month enrollment in Medicaid; one ED or 
hospitalization in the 12 months prior to the intervention; and are 
included as the intervention group in the Cost-Benefit Analysis  
Table 5.1: HHU II Program Recruitment and Participant Flow Diagram 
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5.4. Methods for the calculation of each cost type 
5.4.1. Variables of Interest 
The model for this study contains a number of variables that were collected reflecting 
different points in time.  Variables were collected for the 12 month period prior to the 
baseline month; at the baseline month; for the 12 month period post the baseline month; 
and for the intervention group, the 36 month period of the Healthy Homes University II 
intervention project (Table 5.2). 
Table 5.2: Study Variables Collected at Each Study Phase 
12 month period prior to Baseline Month  
(Pre Period) Baseline month 
12 months post Baseline Month 
(Post Period) 36 month study period 
          for intervention group only 
Number of  outpatient visits* Age at Baseline Number of  outpatient visits* Basic Costs 
Costs of  outpatient visits* Age Group at Baseline: Costs of  outpatient visits* Custom Costs  
Number emergency department visits* < 3 years Number emergency department visits* Custom Partner Costs 
Costs of emergency department visits* 3-5 years Costs of emergency department visits* Total Remediation Costs 
Number of inpatient stays* 6-12 years Number of inpatient stays* Marginal Staff Costs 
Costs of  inpatient stays* 13-<19 years Costs of  inpatient stays* Total Marginal Costs 
Number prescriptions filled* Gender Number prescriptions filled* Direct Costs 
Costs of prescriptions filled* Race Costs of prescriptions filled* Total Direct Costs  
          Indirect Costs 
          Full Costs 
* all services asthma-related           
 
Key demographic variables were obtained from the Medicaid database, including the 
child’s age at baseline, gender, and race.  The child’s date of birth was used to compute 
the child’s age at the baseline month, which was a continuous variable.  An age group 
at baseline variable was created which was nominal.  The gender and race variables 
were also nominal variables. To assess the utilization of asthma-related medical 
services, the total number of asthma-related OP visits, ED visits, IP stays, and 
prescriptions filled were obtained from the Medicaid claims records of each child for the 
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12 months prior to the baseline month; and separately, for the 12 months post the 
baseline month.  
5.4.2. Identification of Asthma-related Services by Place of Service 
5.4.2.1. Outpatient Costs 
Outpatient services were identified if the procedure code was 99201-99205; 99211-
99215; or 99241-99245, and were flagged as asthma related if the ICD-9 was in the 493 
series (Table 5.3). 
 
ICD-9 Codes  
Asthma 493 
 493.0 Extrinsic asthma 
 493.00 Extrinsic asthma, unspecified  
 493.01 Extrinsic asthma with status asthmaticus  
 493.02 Extrinsic asthma with (acute) exacerbation 
 493.1 Intrinsic asthma 
 493.10 Intrinsic asthma, unspecified  
 493.11 Intrinsic asthma with status asthmaticus  
 493.12 Intrinsic asthma with (acute) exacerbation  
 493.2 Chronic obstructive asthma 
 493.20 Chronic obstructive asthma, unspecified  
 493.21 Chronic obstructive asthma with status asthmaticus  
 493.22 Chronic obstructive asthma with (acute) exacerbation  
 493.8 Other forms of asthma 
 493.81 Exercise induced bronchospasm  
 493.82 Cough variant asthma convert 493.82 to ICD-10-CM 
 493.9 Asthma unspecified 
 493.90 Asthma,unspecified type, unspecified 
 493.91 Asthma, unspecified type, with status asthmaticus  
 493.92 Asthma, unspecified type, with (acute) exacerbation  
 
Table 5.3: Chronic Obstructive Pulmonary Disease and Allied Conditions 
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Facility fee screens were obtained from the Michigan MDCH Physician Primary Care 
Rate Increase Initiative Database, January 2014. The non-facility fee for events 
occurring outside of southeast Michigan was attached to each event and calculated.  
The events were then assigned to period 1 or period 2, by beneficiary. Finally, the total 
number of outpatient visits for period 1 and period 2, as well as the total cost for each 
period was calculated for each case. 
5.4.2.2. ED costs 
Emergency Department services for each event were identified if the Revenue Flag 
code was in the 450 series (045X) and if the cases were flagged as asthma related if 
the ICD-9 was in the 493 series (Table 5.3). 
The Department of Health and Human Services, Centers for Medicare & Medicaid 
Services (CMS), Outpatient Prospective Payment System (OPPS) determines payment 
amounts for designated hospital outpatient services. The OPPS generally applies to 
designated hospital outpatient services furnished in all classes of hospitals, although 
there are a few exceptions which do not apply to this study. In most cases, the unit of 
payment under the OPPS is the Ambulatory Payment Classifications (APC). CMS 
assigns individual services (Healthcare Common Procedure Coding System [HCPCS] 
codes) to APCs based on similar clinical characteristics and similar costs. The payment 
rate and copayment calculated for an APC apply to each service within the APC. Within 
each APC, payment for dependent, ancillary, supportive, and adjunctive items and 
services are packaged into payment for the primary independent service [54]. 
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The final OPPS Ambulatory payment classifications (APCs) for calendar year 2014 
were obtained from CMS.  Each event’s HCPCS procedure code was matched to the 
corresponding APC code and relative weight, (Addendum B.-Final OPPS Payment by 
HCPCS Code for CY 2014) to determine the corresponding payment rate for the facility 
charge. The professional fee charge for each event’s HCPCS procedure code was 
determined from the MDCH Physician Primary Care Rate Increase Initiative Database, 
January 2014, and added to the facility charge, to determine a cost for each event.  The 
rates used were for Michigan Locality 99 (all counties not included in the Locality 01 
area of SE Michigan).The events were then assigned to period 1 or period 2, by for 
each case. Finally, the total number of emergency department visits for period 1 and 
period 2, as well as the total cost for each period was calculated for each case. 
5.4.2.3. Inpatient Costs 
CMS uses a prospective payment system (PPS) model to control costs. This system is 
a per-case reimbursement mechanism under which inpatient admission cases are 
divided into relatively homogeneous categories called Medicare Severity Diagnosis 
Related Groups (MS-DRGs),commonly known as DRGs. Hospitals are typically paid a 
set fee for treating all patients in a DRG, regardless of the actual cost for that case. One 
DRG is assigned to each inpatient stay. The DRGs are assigned using the principal 
diagnosis and additional diagnoses, the principal procedure and additional procedures, 
sex and discharge status. Diagnoses and procedures assigned by using ICD-9-CM 
codes determine the MS-DRG assignment.  
Each DRG is assigned a weight. The weight is used to adjust for the fact that different 
types of patients consume different resources and have different costs. Groups of 
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patients who are expected to require above average resources have a higher weight 
than those who require fewer resources. Weights are updated annually to reflect 
changes in medical practice patterns, use of hospital resources, diagnostic and 
procedural definitions and DRG assignment criteria [54].  
In this DRG prospective payment system, Medicare pays hospitals a flat rate per case 
for inpatient hospital care so that efficient hospitals are rewarded for their efficiency and 
inefficient hospitals have an incentive to become more efficient [54]. 
DRG codes were obtained for each event.  Events which were coded with DRG codes 
202-203 (Table 5.4) were determined to be asthma-related.  If the DRG code was 
missing then the ICD-9 code was evaluated, and if it was in the in the 493 series (Table 
5.3), it was determined to be an asthma-related event. The relative weight to be used 
for each DRG was obtained from MDCH, Medicaid Grouper 31.0, for calendar year 
2014.   The Michigan Medicaid Hospital DRG rates for 2014 were obtained from the 
Michigan Medicaid website. The average total operating cost and capital cost was 
calculated for all in state hospitals, which was $4188 (Michigan Medicaid Hospital DRG 
rates; 2014).This average DRG cost was used as the hospital multiplier to calculate 
inpatient stay costs for each event according to its specific DRG. The events were then 
assigned to period 1 or period 2, by beneficiary. Finally, the total number of inpatient 
stays for period 1 and period 2, as well as the total cost for each period was calculated 
for each case. 
  
  
78 
 
Table 5.4: DRG Codes used to identify Asthma-Related Inpatient Stays 
DRG Codes  Description 
    
202 Bronchitis & asthma w CC/MCC 
202.1 Bronchitis & asthma w CC/MCC 
203 Bronchitis & asthma w/o CC/MCC 
203.1 Bronchitis & asthma w/o CC/MCC 
 
5.4.2.4. Rx Costs 
Prescription drugs were flagged as asthma related if they were identified as an Asthma 
Controller and Reliever Medications according to HEDIS (the Healthcare Effectiveness 
Data and Information Set) (Table 5.5).  The drugs were then classified as controller or 
rescue drugs according to the HEDIS guidelines.  The dispensing date, days supply and 
NDC code were obtained for each prescription claim.  A dispensing event was defined 
using HEDIS guidelines, as one prescription of an amount lasting 30 days or less. If 
multiple prescriptions for the same medication were dispensed on the same day, the 
days supply was summed and divided by thirty. Dispensing events were calculated 
based on HEDIS specifications.  The National Average Drug Acquisition Cost (NADAC) 
for Medicaid Covered Outpatient Drugs was obtained from the Centers for Medicaid and 
Medicare Services, for the week of November 14, 2014, and was used to calculate 
prescription costs. Unit costs and pricing units were obtained, and if a generic drug was 
available, the generic price was used. Costs were calculated for each prescription 
based on the days supply, cost per unit, and unit packaging. Standard dispensing fees 
were obtained from Medicaid Services Administration, Bulletin MSA-09-58, and added 
to the prescription cost. 
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The month each prescription was filled was assigned to period 1 or period 2, by 
beneficiary. Finally, the total numbers of asthma-related prescription fills were 
calculated for period 1 and period 2, as well as the total cost of all the prescriptions for 
each period, for each beneficiary. 
 
Table 5.5: Asthma Controller and Reliever Medications 
Asthma Controller Medications 
Description Prescriptions 
Antiasthmatic 
combinations 
• Dyphylline-guaifenesin • Guaifenesin-theophylline  
Antibody inhibitors • Omalizumab   
Inhaled steroid 
combinations 
• Budesonide-formoterol • Fluticasone-salmeterol • Mometasone-formoterol 
Inhaled corticosteroids • Beclomethasone 
• Budesonide 
• Ciclesonide 
• Flunisolide 
• Fluticasone CFC free 
• Mometasone  
• Triamcinolone 
 
Leukotriene modifiers • Montelukast • Zafirlukast • Zileuton 
Mast cell stabilizers • Cromolyn  
Methylxanthines • Aminophylline • Dyphylline • Theophylline 
Asthma Reliever Medications 
Description Prescriptions 
Short-acting, inhaled 
beta-2 agonists 
• Albuterol 
• Levalbuterol 
• Metaproterenol 
• Pirbuterol 
 
 
http://www.ncqa.org/HEDISQualityMeasurement/HEDISMeasures/HEDIS2013/HEDIS2013FinalNDCLists.aspx 
Table AMR-A 
 
 
5.5. Statistical Analysis Methods 
The data processing and statistical analyses for this study was performed using the 
Statistical Package for the Social Sciences (SPSS), Version 22 (IBM Software). 
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5.5.1. Descriptive Statistics 
Descriptive analyses of the children enrolled in the study were conducted, describing 
the age distribution (<1-2yrs, 3-5yrs, 6-12 yrs, 13-<19 yrs), gender, and race of enrolled 
children for the control and intervention group (Chapter 6; Table 6.1).  
Two group, pre/post intervention analyses using the Mann-Whitney non-parametric test 
for independent samples for a significant improvement (P<.05) in specific outcomes was 
used.  Unadjusted differences in the average costs of care were calculated between the 
cohorts, and the frequency of each outcome was described in the population. Outcomes 
to be tested were asthma-related outpatient visits, asthma-related outpatient costs, 
asthma-related ED visits, asthma-related ED costs, asthma-related hospitalizations, 
asthma-related hospitalization costs, asthma-related controller and reliever prescriptions 
filled, asthma-related controller and reliever prescription costs, and overall asthma-
related costs. Means with standard deviation, medians, and interquartile ranges were 
reported for all the variables. 
Utilization 
Descriptive statistics of asthma-related medical care utilization were calculated for the 
variables of interest for the pre-intervention period, comparing the control and 
intervention groups (Chapter 6; Tables 6.2, 6.3). Correlation coefficients were generated 
to test for relationships between each independent and dependent variables. 
Descriptive statistics of asthma-related medical care utilization were calculated for the 
variables of interest for the post-intervention period, comparing the control and 
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intervention groups (Chapter 6; Tables 6.4, 6.5). Correlation coefficients were generated 
to test for relationships between each independent and dependent variables. 
The difference in asthma-related utilization for each group between the pre period and 
the post period were calculated for each group, and descriptive statistics were reported. 
Correlation coefficients were generated to test for relationships between each 
independent and dependent variables (Chapter 6; Tables 6.6, 6.7). 
Costs 
Descriptive statistics of asthma-related medical care costs were calculated for the 
variables of interest for the pre-intervention period, comparing the control and 
intervention groups (Chapter 6; Tables 6.8, 6.9). Correlation coefficients were generated 
to test for relationships between each independent and dependent variables. 
Descriptive statistics of asthma-related medical care costs were calculated for the 
variables of interest for the post-intervention period, comparing the control and 
intervention groups (Chapter 6; Tables 6.10, 6.11). Correlation coefficients were 
generated to test for relationships between each independent and dependent variables. 
The difference in asthma-related medical care costs for each group between the pre 
period and the post period were calculated for each group, and descriptive statistics 
were reported. Correlation coefficients were generated to test for relationships between 
each independent and dependent variables (Chapter 6; Tables 6.12, 6.13). 
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5.5.2. General linear regression 
General linear regression was used to determine any changes in utilization during the 
pre and post periods, adjusting for age at baseline, race, and gender.  The mean and 
standard error were reported for the control and intervention group, and a significance 
test was reported at p <.05 (Chapter 6; Tables 6.14 - 6.26). 
General linear regression was used to determine any changes in medical care costs 
during the pre and post periods, adjusting for age at baseline, race, and gender.  The 
mean and standard error were reported for the control and intervention group, and a 
significance test was reported at p <.05 (Chapter 6; Tables 6.27-6.29). 
5.5.3. Exclusion of outliers 
Because the data was not normally distributed, some analyses were conducted 
removing the outliers, notably a comparison of means for the change in utilization 
between the two groups. For each variable of interest, outliers were removed for that 
specific interest area, and noted in the table (Chapter 6, Table 6.30).  
Similarly, a comparison of means for the change in costs between the two groups was 
also conducted, with the respective outliers removed for each variable of interest in the 
analysis (Chapter 6, Table 6.31).  
5.5.4. General Linear Regression with the Exclusion of Outliers 
General linear regression was used to determine any changes in medical care costs 
during the pre and post periods, adjusting for age at baseline, race, and gender.   Each 
type of medical care (emergency department visits, inpatient stays, prescriptions and 
outpatient costs) was run separately with its respective outliers removed. The mean and 
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standard error were reported for the control and intervention group, and a significance 
test was reported at p <.05 (Chapter 6; Tables 6.32-6.35).  The model for total medical 
costs with outliers removed was also run to determine any changes in medical care 
costs during the pre and post periods, adjusting for race only (Chapter 6, Table 6.36). 
5.5.5. Comparisons of Cost Calculations 
The unadjusted net benefit of the intervention on total medical costs was compared 
against: a regression model; an unadjusted net benefit of the intervention on total 
medical costs with outliers removed; a regression model of the adjusted net benefit of 
the intervention on total medical costs with outliers removed; and finally, a regression 
model of the adjusted net benefit of the intervention on total medical costs with outliers 
removed, and controlling only for race (Chapter 6, Table 6.36). 
5.5.6. Models including intervention costs 
This section compares the marginal, direct, and full costs of the intervention described 
in Chapter 4 (see Tables 4.3 – 4.8 and Figures 4.1 – 4.3) against the healthcare savings 
for each calculation method (unadjusted change in costs, adjusted change in costs, 
unadjusted change in costs without outliers, and adjusted change in costs without 
outliers) (see Chapter 6, Table 6.13). 
5.5.7. Protection of rights of human subjects 
The Michigan Department of Community Health (MDCH)  IRB was obtained on 
10/15/2013  under the title “Healthy Homes University Evaluation and Cost-Benefit 
Analysis”; it was approved by expedited review without modifications, MDCH IRB Log # 
201310-07-EA. 
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The Health Sciences and Behavioral Sciences Institutional Review Board serving the 
University of Michigan Main Campus, reviewed the proposal, “Evaluation of Cost 
Implications of an Asthma Healthy Homes Intervention Program”, HUM00099348, on 
03/02/15 and gave a Notice of Determination of “Not Regulated” Status.  It was 
determined that IRB approval was not required as the data cannot be tracked to a 
human subject.  
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Chapter 6 
Results 
6.1. Subject Characteristics 
Of the 240 participants in the Healthy Homes University II project, 40 participants met 
the inclusion criteria for the study, and were identified as the intervention group (I).  
Eighty individuals were identified for the control group (C).  The control group had a 
larger percentage of Black children(C=55%, I=38%), whereas the intervention group 
had a larger percentage of Hispanic participants (C=3%, I=18%). Gender Distribution 
were similar between the two groups, with over 65 of participants being male in both 
groups (C=65%, I=68%).  Age at baseline were similar for both groups, with over 55% 
of subjects being 5 years or under (C=59%, I=57%), and over 27% of subjects in both 
groups being age 2 or under (C=33%, I=27%). None of the demographic characteristics 
were significantly different between the two groups (Table 6.1). 
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Table 6.1: Baseline Demographic Information for Healthy Home University II Cost-Benefit Study 
    Control Intervention   p-value 
                
    Number % Number %     
                
Age at Baseline           0.494 
Less than or equal to 2 yrs 26 32.50% 6 26.67%     
3 to 5 years 21 26.25% 15 30.00%     
6 to 12 years 18 22.50% 16 28.33%     
13 to less than 19 years 15 18.75% 3 15.00%     
TOTAL   80 100.00% 40 100.00%     
                
Race             0.788 
Black   44 55.00% 15 37.50%     
White   27 33.75% 17 42.50%     
Hispanic   2 2.50% 7 17.50%     
Other   7 8.75% 1 2.50%     
TOTAL   80 100.00% 40 100.00%     
                
Gender             0.238 
Male   52 65.00% 27 67.50%     
Female   28 35.00% 13 32.50%     
TOTAL   80 100.00% 40 100.00%     
 
6.2. Utilization of Services 
There were two areas of asthma-related medical care utilization which were statistically 
significant between the two groups during pre-intervention period, prescription use and 
outpatient visits (Table 6.2 and Table 6.3). It is important to note that cases included in 
the intervention and control groups were selected based on minimum levels of 
utilization, not average utilization – i.e. they experienced either an ED visit or an 
inpatient stay with a primary diagnosis of asthma in the 12 months of the “pre” period.   
6.2.1. Pre period 
Prescription Use 
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There is a statistically significant difference in the utilization of both controller and 
reliever medications between the control and intervention groups in the Pre period, with 
the intervention group using twice as many controller medications (C=2.45, I=5.70, 
p=<.001), and one and a half times as many rescue medications (C=2.99, I=4.53, 
p=<.001) (Table 6.2). 
 
Table 6.2: Unadjusted Utilization of Asthma Controller and Rescue Prescriptions, during the PRE 
period between HHU II intervention and control groups 
 
  CONTROL INTERVENTION   
                    
  Mean Median S.D.  IQR Mean Median S.D. IQR P-Value*  
                  (means) 
RX Controller Scripts Pre 2.45 1.00 3.14 4.00 5.70 4.00 5.29 7.75 0.00 
RX Rescue Scripts Pre 2.99 2.00 2.88 4.00 4.53 4.00 3.15 4 0.00 
* significance level is .05; independent samples Mann-Whitney U test 
 
ED Utilization 
There was no statistically significant difference in the mean number (C=1.46, I=1.48, 
p=.596) and median number (C=1.0, I=1.0, p=.823) of asthma-related emergency 
department visits between the two groups in the 12 months prior to the intervention 
month (Table 6.3).  Both groups averaged about 1.5 ED visits during the pre-
intervention period. 
Inpatient Utilization 
There was not a statistically significant difference in the mean number (C=0.20, I=0.45, 
p=.116) and median number (C=0.0, I=0.0, p=.246) of asthma-related inpatient stays 
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between the two groups in the 12 months prior to the intervention month (Table 6.3). On 
average, both groups did not experience an inpatient stay during the pre-intervention 
period, although the intervention rate was double that of the control group. 
Outpatient Utilization 
There was a statistically significant difference in the mean number of asthma-related 
outpatient visits during the 12 months prior to the intervention month (C=0.95, I=3.05, 
p<.001) between the two groups, with the intervention group averaging three times as 
many visits as the control group (Table 6.3).  There was also a significant difference in 
the median number of asthma-related outpatient visits used in the 12 months prior to 
the intervention month, with the intervention median being twice as much as the control 
group. (C=1.0, I=2.0, p<.001).   
 
Table 6.3 Unadjusted Utilization of Asthma-Related Emergency Department, Inpatient, Outpatient 
Services during the PRE period between HHU II intervention and control groups 
  CONTROL INTERVENTION     
                      
  Mean Median S.D. IQR Mean Median S.D. IQR P-Value*  P-Value*  
                  (medians) (means) 
ED Visits 1.46 1.00 1.38 0.00 1.48 1.00 1.47 1 0.823 0.596 
IP Stays 0.20 0.00 0.43 0.00 0.45 0.00 0.81 1 0.246 0.116 
OP Visits 0.95 1.00 1.23 1.75 3.05 2.00 2.96 3.75 <.001 <.001 
* significance level is .05; independent samples Median test and Mann-Whitney U test 
 
 
 
6.2.2. Post period 
Descriptive statistics of asthma-related medical care utilization were calculated for the 
variables of interest for the post-intervention period, comparing the control and 
  
89 
 
intervention groups. The same two services, prescription use and outpatient visits, had 
statistically significant differences in the post-intervention period as well (Table 6.4 and 
Table 6.5). 
Prescription Use 
There was a statistically significant difference in the utilization patterns of both controller 
and rescue medications between the control and intervention groups in the Post period, 
with the intervention group using two and a half times as many controller medications 
(C=2.97, I=7.70, p=<.001), and more than one and a half times as many rescue 
medications (C=3.09, I=5.13, p=<.001) (Table 6.4). 
 
Table 6.4: Unadjusted Utilization of Asthma Controller and Rescue Prescriptions, during the POST 
period between HHU II intervention and control groups 
  CONTROL   INTERVENTION   
                      
  Mean Median S.D.  IQR   Mean Median S.D. IQR P-Value*  
                    (means) 
RX Controller Scripts Post 2.97 1.00 3.71 5.00   7.70 6.00 6.65 10.75 0.00 
RX Rescue Scripts Post 3.09 2.00 3.88 3.25   5.13 4.50 3.76 5.75 0.00 
* significance level is .05; independent samples Mann-Whitney U test 
 
 
ED Utilization 
There was no significant difference in the mean number (C=0.53, I=0.70, p=.777) and 
median number (C=0.0, I=0.0, p=.839) of asthma-related emergency department visits 
between the two groups in the 12 months post the intervention month.  Both groups 
averaged less than 1 ED visit during the post-intervention period (Table 6.5).  
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Inpatient Utilization 
There was no significant difference in the mean number (C=0.13, I=0.08, p=.942) and 
median number (C=0.0, I=0.0, p=.713) of asthma-related inpatient stays between the 
two groups in the 12 months post the intervention month. On average, both groups did 
not experience an inpatient stay during the post-intervention period. However the 
intervention group experienced almost half as many inpatient stays as the control group. 
This is in contrast to the pre intervention period, when the intervention group had 
experienced double the number of inpatient stays as compared to the control group 
(Table 6.5). 
Outpatient Utilization 
There was a statistically significant difference in the mean number of asthma-related 
outpatient visits during the 12 months post the intervention month (C=0.96, I=2.33, 
p<.001) between the two groups, with the intervention group averaging two times as 
many visits as the control group.  This is a reduction from the pre period, when the 
intervention group experienced three times as many asthma-related outpatient visits as 
the control group.  There was also a significant difference in the median number of 
asthma-related outpatient visits used in the 12 months post the intervention month, with 
the intervention median being twice as much as the control group. (C=0.0, I=2.0, 
p=.005) (Table 6.5).   
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Table 6.5: Unadjusted Utilization of Asthma-Related Prescriptions Medications, Emergency 
Department, Inpatient, and Outpatient Services during the POST period between HHU II 
intervention and control groups 
  CONTROL   INTERVENTION     
                        
  Mean Median S.D. IQR   Mean Median S.D. IQR P-Value*  P-Value* 
                    (medians)  (means) 
ED Visits 0.53 0.00 0.87 1.00   0.70 0.00 1.20 1 0.893 0.777 
IP Stays 0.13 0.00 0.46 0.00   0.08 0.00 0.27 0 0.713 0.942 
OP Visits 0.96 0.00 1.41 1.75   2.33 2.00 2.43 4 0.005 <.001 
                        
* significance level is .05; independent samples Median test and Mann-Whitney U test 
 
 
6.2.3. Difference in Utilization Pre – Post 
The difference in asthma-related utilization for each group between the pre period and 
the post period were calculated. There was a statistically significant change in utilization 
of asthma controller medications (Table 6.6), as well as inpatient visits between the two 
groups (Table 6.7). 
Prescription Use 
There is a statistically significant difference in the change in utilization of asthma 
controller and rescue medications between the two groups between the two time 
periods, with the intervention group increasing its use of controller medications four 
times as much as the control group (C=-0.53, I=-2.00, p=<.03). The change in the 
difference of utilization patterns of the rescue medications between the two groups was 
not statistically significant, although the intervention group increased its use of rescue 
medications more than the control group(C=-0.10, I=-0.60, p=<.47) (Table 6.6). As the 
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numbers are negative, this indicates an increase in the use of rescue medications for 
both groups. 
 
Table 6.6: Unadjusted Benefit of Asthma Controller and Rescue Prescriptions between HHU II 
intervention and control groups 
  CONTROL INTERVENTION     
                      
  Mean Median S.D.  IQR Mean Median S.D. IQR P-Value*  Net benefit 
                  (means)   
RX Controller 
Scripts -0.53 0.00 3.07 3.00 -2.00 -1.00 3.34 3.75 0.03 -1.47 
RX Rescue Scripts -0.10 0.00 3.16 2.25 -0.60 0.00 3.66 4.75 0.47 -0.50 
* significance level is .05; independent samples Mann-Whitney U test   
 
ED Utilization 
There was no significant difference in the change of the mean number (C=0.94, I=0.78, 
p=.626) and median number (C=1.0, I=1.0, p=.341) of asthma-related emergency 
department visits between the two groups, during the two time periods.  However, both 
groups averaged a decrease in the number of ED visits during the post-intervention 
period, with a median difference of 1 in both groups (Table 6.7).   
Inpatient Utilization 
There was a statistically significant difference in the change of the mean number 
(C=0.08, I=0.38, p=.024) of asthma-related inpatient stays between the two groups, 
during the two time periods.  Both groups experience a decrease in the average number 
of inpatient stays.  However, the intervention group, which had experienced twice as 
many inpatient stays as related to the control group during the pre-intervention period, 
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experienced half as many inpatient stays during the post intervention period, accounting 
for this important finding, that the intervention did have a significant effect in decreasing 
the number of inpatient visits (Table 6.7).  
Outpatient Utilization 
There was not a statistically significant difference in the change of the mean number 
(C=-.01, I=0.73, p=.166) of asthma-related outpatient visits between the two groups, 
during the two time periods.  The intervention group experienced a decrease in the 
average number of outpatient visits, while the control group experienced a slight 
increase. This decrease was more than proportional, even though it did not reach 
significance (Table 6.7). 
 
Table 6.7: Unadjusted Benefit of Asthma-Related Emergency Department, Inpatient, and 
Outpatient Use between HHU II intervention and control groups  
  CONTROL   INTERVENTION       
                          
  Mean Median S.D. IQR   Mean Median S.D. IQR P-Value*  P-Value*  Net benefit 
                    (medians) (means)   
ED Visits 0.94 1.00 1.54 1   0.78 1.00 1.64 1 0.341 0.626 -0.16 
IP Stays 0.08 0.00 0.47 0   0.38 0.00 0.74 1 0.059 0.024 0.30 
OP Visits -0.01 0.00 1.42 2   0.73 0.00 2.84 3 0.201 0.166 0.74 
                          
* significance level is .05; independent samples Median test and Mann-Whitney U test   
 
6.3. Costs of Services 
The difference in asthma-related medical care costs between the pre period and the 
post period were calculated for each group, and descriptive statistics were reported. 
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Correlation coefficients were generated to test for relationships between each 
independent and dependent variables (Table 6.9). 
It is important to note that costs were calculated as utilization multiplied by actual 2014 
prices. Since prices are the same for both groups for both periods, the results for costs 
should be similar to the results for utilization.  However, the mix of the specific types of 
drugs and visits could be different. 
6.3.1. Pre period 
Descriptive statistics of asthma-related medical care costs were calculated for the 
variables of interest for the pre-intervention period, comparing the control and 
intervention groups (Table 6.9). Correlation coefficients were generated to test for 
relationships between each independent and dependent variables. 
Prescription Costs 
There was a statistically significant difference in the mean cost of asthma-related 
prescriptions used in the 12 months prior to the intervention month, with the intervention 
group costing twice as much as the control group (C=$453, I=$925, p<.001).  There was 
also a difference in the median cost of asthma-related prescriptions used in the 12 
months prior to the intervention month, again with the intervention group’s median cost 
being almost twice as much as the controls’ cost (C=$233, I=$448, p<.081).  
When separated into types of asthma-related prescriptions, controller or rescue 
medications, there is a statistically significant difference in the costs of both of these 
medications between the two groups in the Pre period, with the intervention group’s 
mean cost of controller medications costing twice as much as the control group 
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(C=$393, I=$795, p=<.001), and as well as the mean cost of the rescue medications 
costing twice as much as the control group (C=$72, I=$130, p=<.0001) (Table 6.8). 
 
Table 6.8: Unadjusted Costs of Asthma Controller and Rescue Drugs during the PRE period 
among HHU II participants and a control group 
 
  CONTROL INTERVENTION   
                    
  Mean Median S.D. IQR Mean Median S.D. IQR P-Value* 
                  (Mean) 
Pre-RX Controller Costs $393 $224 662.93 612.78 $795 $649 673.58 901.30 0.000 
Pre-RX Rescue Costs $72 $37 105.49 87.61 $130 $95 109.79 176.91 0.000 
* significance level is .05; independent samples Mann-Whitney U test 
 
ED Costs 
There was no significant difference in the mean cost (C=$385, I=$482, p=.126) and 
median number (C=$263, I=$390, p=.081) of asthma-related emergency department 
visits between the two groups in the 12 months prior to the intervention month (Table 
6.9).  Both groups averaged over $385 during the pre-intervention period. 
Inpatient Costs 
There was no significant difference in the mean cost (C=$1358, I=$1167, p=.205) and 
median number (C=0.0, I=0.0, p=.246) of asthma-related inpatient stays between the 
two groups in the 12 months prior to the intervention month (Table 6.9). 
Outpatient Costs 
There was a statistically significant difference in the mean cost of asthma-related 
outpatient visits during the 12 months prior to the intervention month (C=$71, I=$272, 
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p<.001) between the two groups, with the intervention group costing almost four times 
as much as the control group (Table 6.9).  There was also a significant difference in the 
median cost of asthma-related outpatient visits used in the 12 months prior to the 
intervention month, with the intervention median coast being four times as much as the 
control group. (C=$42, I=$175, p<.001).   
Total Medical Costs 
There was a statistically significant difference in total medical costs during the Pre 
intervention period between the two groups (C=$2268, I=$2845, p<.001).  The 
intervention group spent $577 more on total medical costs as compared to the control 
group during the Pre intervention period (Table 6.9). 
 
Table 6.9 Unadjusted Costs of Asthma-related Care during the PRE period among HHU II 
participants and a control group 
 
 
Mean Median S.D. IQR Mean Median S.D. IQR P-Value* P-Value* Difference
(Median) (Mean)
RX Costs $453 $233 730.65 666.80 $925 $735 741.42 1027.81 <.001 <.001 $472
ED Costs $385 $263 389.98 192.80 $482 $390 448.35 289.48 0.081 0.126 $97
IP Costs $1,358 $0 5016.42 0.00 $1,167 $0 2287.24 2366.64 0.246 0.205 -$192
OP Costs $71 $42 100.43 99.51 $272 $175 273.29 295.72 <.001 <.001 $201
Total Medical Costs $2,268 $737 5241.53 1133.42 $2,845 $2,137 2664.88 2575.86 <.001 <.001 $577
* significance level is .05; independent samples Median test and Mann-Whitney U test
INTERVENTIONCONTROL
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6.3.2. Post period 
Descriptive statistics of asthma-related medical care costs were calculated for the 
variables of interest for the post-intervention period, comparing the control and 
intervention groups (Tables 6.10 and 6.11).   
Prescription Costs 
There was a statistically significant difference in the mean cost of asthma-related 
prescriptions used in the 12 months post the intervention month, with the intervention 
group costing twice as much (C=$469, I=$1074, p<.001) (Table 6.10).  There was also 
a statistically significant difference in the median cost of asthma-related prescriptions 
used in the 12 months post the intervention month, with control group median $208 and 
the intervention group median $863, four times as high (C=$208, I=$863, p<.001).   
When separated into types of asthma-related prescriptions, controller or rescue 
medications, there is a statistically significant difference in the costs of both of these 
medications between the two groups in the Post period, with the intervention group’s 
mean cost of controller medications costing twice as much as the control group 
(C=$450, I=$1056, p=<.001), and as well as the mean cost of the rescue medications 
costing twice as much as the control group (C=$75, I=$158, p=<.001) (Table 6.10). 
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Table 6.10: Unadjusted Costs of Asthma Controller and Rescue Drugs during the POST period 
among HHU II participants and a control group 
 
 
ED Costs 
There was no significant difference in the mean cost (C=$149, I=236, p=.126) and 
median number (C=0, I=0.0, p=.081) of asthma-related emergency department visits 
between the two groups in the 12 months post the intervention month (Table 6.11). 
Inpatient Costs 
There was no significant difference in the mean cost (C=$334, I=$203, p=.205) of 
asthma-related inpatient stays between the two groups in the 12 months post the 
intervention month (Table 6.11).  
Outpatient Costs 
There was a statistically significant difference in the mean cost of asthma-related 
outpatient visits during the 12 months post the intervention month (C=$74, I=$246, 
p<.001) between the two groups, with the intervention group costs averaging three 
times as much as the control group.  There was also a significant difference in the 
median difference in costs between both groups(C=0.0, I=$142, p=.005) (Table 6.11).   
Mean Median S.D. IQR Mean Median S.D. IQR P-Value*
(Mean)
RX Controller Costs $450 $193 943.68 597.02 $1,056 $838 949.13 1179.66 0.000
RX Rescue Costs $75 $41 119.08 103.03 $158 $137 129.84 184.73 0.000
 
             
CONTROL INTERVENTION
* significance level is .05; independent samples Mann-Whitney U test
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Total Medical Costs 
There was a statistically significant difference in total medical costs during the Post 
intervention period between the two groups (C=$1026, I=$1759, p<.001).  The 
intervention group spent $733 more on total medical costs as compared to the control 
group during the Post intervention period (Table 6.11). 
Table 6.11: Unadjusted Costs of Asthma-related Care during the POST period among HHU II 
participants and a control 
 
 
6.3.3. Difference in Costs Pre – Post 
Prescription Costs 
There was not a significant difference in the change of the mean cost of asthma-related 
prescriptions used in the 12 months pre compared to the 12 months post the 
intervention month, (C=-$16, I=-149, p<.397).  Both groups increased their prescription 
costs slightly (Table 6.13).  
When separated into types of asthma-related prescriptions, controller or rescue 
medications, there is almost a statistically significant difference in the change in costs of 
controller medications between the two groups between the two time periods, with the 
Mean Median S.D. IQR Mean Median S.D. IQR P-Value* P-Value* Difference
(Median) (Mean)
RX Costs $469 $208 950.08 586.40 $1,074 $863 946.82 1253.86 <.001 <.001 $605
ED Costs $149 $0 258.41 246.50 $236 $0 418.78 390.14 0.081 0.126 $87
IP Costs $334 $0 1202.48 0.00 $203 $0 733.76 0.00 0.246 0.205 -$131
OP Costs $74 $0 109.82 104.79 $246 $142 259.71 414.91 <.001 <.001 $172
Total Medical  Costs $1,026 $378 1717.53 958.66 $1,759 $1,434 1744.96 1869.62 <.001 <.001 $733
INTERVENTION
 
                 
* significance level is .05; independent samples Median test and Mann-Whitney U test
CONTROL
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intervention group increasing its use of controller medications four times as much as the 
control group (C=-$57, I=-$260, p=<.055). The change in the cost of controller 
medications increased by $204 in the intervention group as compared to the controller 
group. The change in the difference of costs of the rescue medications between the two 
groups was not statistically significant, although the cost of the rescue medications 
increased by $28 for the intervention group, compared to $3 for the control group, for a 
net change of $25 more for the intervention group (C=-$3, I=-$28, p=<.39) participants 
and a control group (Table 6.12). 
 
Table 6.12: Unadjusted Change in Costs of Asthma-Controller and Rescue Drugs among HHU II 
participants and a control group 
 
 
ED Costs 
There was no significant difference in the change of the mean cost (C=$236, I=$245, 
p=.626) of asthma-related emergency department visits between the two groups, during 
the two time periods.  However, both groups averaged a similar decrease in the mean 
cost of their ED visits during the post-intervention period. 
  
Mean Median S.D. IQR Mean Median S.D. IQR P-Value* Net Cost**
(Mean)
RX Controller Costs $57 $0 526.86 361.93 $260 $102 526.86 361.93 0.055 $204
RX Rescue Costs $3 -$4 89.63 83.00 $28 $14 137.79 155.93 0.394 $25
** Relative cost increase of intervention vs. control
* Significance level is .05; independent samples Mann-Whitney U test
CONTROL INTERVENTION
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Inpatient Costs 
There was no significant difference in the change of the mean cost (C=$1025, I=$964, 
p=.174) of asthma-related emergency department visits between the two groups, during 
the two time periods.  Both groups experience a decrease in the average cost of 
inpatient stays during the post intervention time period of almost $1000 during the 12 
month post intervention period.   
Outpatient Costs 
There was no significant difference in the change of the mean cost (C=-3, I=26, p=.859) 
of asthma-related outpatient visits between the two groups, during the two time periods.  
The intervention group experienced an average savings of $26, while the control group 
increased its average cost by $3. 
Total Medical Costs 
There was no statistically significant difference in the change of the total medical cost 
(C=$1241, I=1085, p=.24) of all asthma-related prescription, emergency department, 
inpatient and outpatient costs between the two groups, during the two time periods.  
The intervention group experienced an average savings of $1085, while the control 
group experienced an average savings of $1241. The control group experienced a net 
savings of $156 greater than the intervention group (Table 6.13). 
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Table 6.13: Unadjusted Change in Costs of Asthma-related Care among HHU II participants and a 
control group 
 
 
6.3.4. General linear regression 
General linear regression was used to determine any changes in utilization during the 
pre and post periods, adjusting for age at baseline, race, and gender.  The mean and 
standard error were reported for the control and intervention groups, and a significance 
test at p <.05. 
Utilization 
Prescription Use 
There was no statistically significant change in the overall utilization of asthma-related 
prescriptions (Table 6.14) between the control and intervention group between the two 
periods. The slope coefficient for dependent variable is group is positive, indicating that 
going from control group to intervention group increases the change in utilization of the 
number of asthma-related scripts. The gender predictor is also positive, indicating that 
going from male to female increases the change in utilization of asthma-related scripts, 
although the change is not statistically significant. The race variables for black (race =1) 
Mean Median S.D. IQR Mean Median S.D. IQR P-Value* P-Value* Difference
(Median) (Mean)
RX Costs -$16 $18 526.77 409.23 -$149 -$33 661.18 789.42 0.846 0.397 -$133
ED Costs $236 $197 392.63 336.74 $245 $263 505.60 545.71 0.333 0.607 $10
IP Costs $1,025 $0 4234.56 0.00 $964 $0 1980.05 2366.64 0.183 0.174 -$61
OP Costs -$3 $0 112.49 141.58 $26 $0 270.99 312.55 0.638 0.859 $29
Total Difference in Costs $1,241 $262 4342.04 861.84 $1,085 $641 1875.19 1764.06 0.175 0.24 -$156
* significance level is .05; independent samples Median test and Mann-Whitney U test
CONTROL INTERVENTION
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and white (race =2) are also positive, indicating an increased change in utilization as 
compared to the ‘other’ category.  The Hispanic group (race = 3) coefficient is negative, 
indicating a decrease in change in utilization as compared to the ‘other’ race group. Age 
at baseline is statistically different between the intervention and control groups, 
indicating that as age increases, it has a positive effect on a change in utilization of 
asthma-related prescriptions overall. 
 
Table 6.14: Multivariate Results Change in Utilization of Asthma-related RX filled between Pre and 
Post Period 
Parameter estimates 
      Interval Hypothesis Test 
Parameter B S.E. Lower Upper Wald Chi-Square df Sig. 
(Intercept) -4.428 2.2817 -8.900 .044 3.766 1 .052 
[Group=0] 1.046 1.0364 -.986 3.077 1.018 1 .313 
[Group=1] 0a             
[Gender=0] .713 .9997 -1.246 2.672 .509 1 .476 
[Gender=1] 0a             
[Race=1] 1.626 1.9407 -2.178 5.429 .702 1 .402 
[Race=2] 1.277 1.9846 -2.613 5.167 .414 1 .520 
[Race=3] -.224 2.5844 -5.290 4.841 .008 1 .931 
[Race=4] 0a             
Age_Baseline 
.246 .1066 .037 .455 5.334 1 .021 
(Scale) 25.796b 3.3302 20.029 33.223       
Dependent Variable: Difference between Pre_RX_NumScripts and Post_RX_NumScripts 
Model: (Intercept), Group, Gender, Race, Age_Baseline     
b. Maximum likelihood estimate.         
 
 
The chi square statistic is much larger than its df (Table 6.15). Therefore, observed 
values deviate significantly from expected values. 
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Table 6.15: Multivariate Results GLM: Change in Utilization of Asthma-related RX filled between 
Pre and Post Period : Goodness of Fit 
 
  Value df Value/df 
Pearson Chi-Square 3095.504 113 27.934 
 
 
Controller Medications 
There was a statistically significant change in the overall utilization of asthma-related 
controller prescriptions (Table 6.16) between the control and intervention group 
between the two periods. The slope coefficient for dependent variable is group is 
positive, indicating that going from control group to intervention group increases the 
change in utilization of the number of asthma-related controller scripts which were filled. 
The gender predictor is also positive, indicating that going from male to female 
increases the change in utilization of asthma-related controller scripts, although the 
change is not statistically significant. The race variables for black (race =1) and white 
(race =2) are also positive, indicating an increased change in utilization as compared to 
the ‘other’ category.  The Hispanic group (race = 3) coefficient is negative, indicating a 
decrease in change in utilization as compared to the ‘other’ race group. Age at baseline 
is statistically significant between the intervention and control groups, indicating that as 
age increases it has a positive effect on a change in utilization of asthma-related 
controller prescriptions overall. 
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Table 6.16: Multivariate Results GLM: Change in Utilization of Asthma-Controller RX filled between 
Pre and Post Period 
Parameter estimates 
      Interval Hypothesis Test 
Parameter B S.E. Lower Upper Wald Chi-Square df Sig. 
(Intercept) -3.602 1.3607 -6.269 -.935 7.006 1 .008 
[Group=0] 1.249 .6182 .037 2.460 4.079 1 .043 
[Group=1] 0a             
[Gender=0] .327 .5969 -.843 1.497 .300 1 .584 
[Gender=1] 0a             
[Race=1] 1.143 1.1544 -1.119 3.406 .981 1 .322 
[Race=2] .148 1.1813 -2.167 2.463 .016 1 .900 
[Race=3] -.391 1.5350 -3.400 2.617 .065 1 .799 
[Race=4] 0a             
Age_Baseline .156 .0638 .031 .282 6.004 1 .014 
(Scale) 9.091b 1.1836 7.044 11.734       
Dependent Variable: Difference between Pre_RX_Cont_NumScripts and Post_RX_Cont_Num 
Scripts 
Model: (Intercept), Group, Gender, Race, 
Age_Baseline       
b. Maximum likelihood estimate.           
 
The chi square statistic is larger than its df (Table 6.17). Therefore, observed values 
deviate significantly from expected values. 
 
Table 6.17: Multivariate Results GLM: Change in Utilization of Asthma-Controller RX filled between 
Pre and Post Period: Goodness of Fit 
 
  Value df Value/df 
Pearson Chi-Square 1072.78 111 9.66 
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Reliever medications 
There was not a statistically significant change in the overall utilization of asthma-
related reliever prescriptions (Table 6.18) between the control and intervention group 
between the two periods. The slope coefficient for dependent variable is group is 
positive, indicating that going from control group to intervention group increases the 
change in utilization of the number of asthma-related controller scripts which were filled. 
The gender predictor is also positive, indicating that going from male to female 
increases the change in utilization of asthma-related controller scripts, although the 
change is not statistically significant. The race variables for black (race =1) and white 
(race =2) are also positive, indicating an increased change in utilization as compared to 
the ‘other’ category.  The Hispanic group (race = 3) coefficient is negative, indicating a 
decrease in change in utilization as compared to the ‘other’ race group. Age at baseline 
is not statistically different between the intervention and control groups, and has a 
minimal effect on a change in utilization of asthma-related rescue prescriptions overall. 
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Table 6.18: Multivariate Results GLM: Change in Utilization of Asthma-Rescue RX filled between 
Pre and Post Period 
Parameter estimates 
      Interval Hypothesis Test 
Parameter B S.E. Lower Upper Wald Chi-Square df Sig. 
(Intercept) -1.686 1.4672 -4.562 1.189 1.321 1 .250 
[Group=0] .466 .6665 -.840 1.772 .489 1 .484 
[Group=1] 0a             
[Gender=0] .371 .6436 -.890 1.633 .333 1 .564 
[Gender=1] 0a             
[Race=1] .075 1.2447 -2.364 2.515 .004 1 .952 
[Race=2] .786 1.2737 -1.710 3.283 .381 1 .537 
[Race=3] -.728 1.6550 -3.972 2.516 .194 1 .660 
[Race=4] 0a             
Age_Baseline .098 .0688 -.037 .233 2.030 1 .154 
(Scale) 10.570b 1.3760 8.189 13.642       
Dependent Variable: Difference between Pre_RX_Rescue_NumScripts and Post_RX_Rescue_ 
NumScripts 
Model: (Intercept), Group, Gender, Race, 
Age_Baseline       
b. Maximum likelihood estimate.           
 
The chi square statistic is larger than its df (Table 6.19). Therefore, observed values 
deviate significantly from expected values. 
 
Table 6.19: Multivariate Results GLM: Change in Utilization of Asthma-Rescue RX filled between 
Pre and Post Period: Goodness of Fit 
 
  Value df Value/df 
Pearson Chi-Square 1247.21 111 11.24 
 
 
 
  
108 
 
ED Use 
There was no statistically significant change in the overall utilization of asthma-related 
emergency department visits (Table 6.20) between the control and intervention group 
between the two periods. The slope coefficient for dependent variable is group is 
negative, indicating that going from control group to intervention group decreases the 
change in utilization of the number of asthma-related emergency department visits. The 
gender predictor is also negative, indicating that going from male to female decreases 
the change in utilization of emergency department visits, although the change is not 
statistically significant. The race variables for black (race =1), white (race =2), and 
Hispanic (race=3) are also negative, and statistically significant, indicating a decreased 
change in utilization of the emergency department as compared to the ‘other’ category 
for all race groups.  Age at baseline is not statistically different between the intervention 
and control groups, having almost no effect on a change in utilization of asthma-related 
emergency department visits overall. 
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Table 6.20: Multivariate Results GLM: Change in Utilization of Asthma-related ED visits between 
Pre and Post Period 
Parameter estimates 
      Interval Hypothesis Test 
Parameter B S.E. Lower Upper Wald Chi-Square df Sig. 
(Intercept) 2.947 .6511 1.671 4.223 20.489 1 .000 
[Group=0] -.082 .2957 -.661 .498 .076 1 .783 
[Group=1] 0a             
[Gender=0] 
-.048 .2853 -.607 .511 .029 1 .865 
[Gender=1] 
0a             
[Race=1] -2.166 .5538 -3.252 -1.081 15.304 1 .000 
[Race=2] -2.032 .5663 -3.142 -.922 12.869 1 .000 
[Race=3] -2.964 .7375 -4.409 -1.518 16.149 1 .000 
[Race=4] 0a             
Age_Baseline 
.009 .0304 -.051 .069 .087 1 .768 
(Scale) 2.101b .2712 1.631 2.705       
Dependent Variable: Difference between Pre_ED_Visits and Post_ED_Visits 
Model: (Intercept), Group, Gender, Race, Age_Baseline   
b. Maximum likelihood estimate.     
 
The chi square statistic is larger than its df (Table 6.21). Therefore, observed values 
deviate significantly from expected values. 
 
Table 6.21: Multivariate Results GLM: Change in Utilization of Asthma-related ED visits between 
Pre and Post Period: Goodness of Fit 
 
  Value df Value/df 
Pearson Chi-Square 252.07 113 2.23 
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Inpatient Stays 
There was a statistically significant change in the overall utilization of asthma-related 
inpatient stays (Table 6.22) between the control and intervention group between the two 
periods. The slope coefficient for dependent variable is group is negative, indicating that 
going from control group to intervention group decreases the change in utilization of the 
number of asthma-related inpatient stays. The gender predictor is positive but very 
small, indicating that going from male to female increases the change in utilization of 
asthma-related inpatient stays very little, and the change is not statistically significant. 
The race variables for black (race =1) and white (race =2) are also positive, indicating 
an increased change in utilization of inpatient stays as compared to the ‘other’ category, 
although the difference is not statistically significant.  The Hispanic group (race = 3) 
coefficient is negative, indicating a decrease in change in utilization of asthma related 
inpatient stays as compared to the ‘other’ race group. Age at baseline is not statistically 
different between the intervention and control groups, and has a small negative effect 
on a change in utilization of asthma-related prescriptions overall. 
The change in inpatient stays is significant at p<.05 (C=0.0, I=0.32, p=.006) (Tables 
6.22, 6.23). 
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Table 6.22: Multivariate Results GLM: Change in Utilization of Asthma-related IP visits between 
Pre and Post Period 
Parameter estimates 
      Interval Hypothesis Test 
Parameter B S.E. Lower Upper Wald Chi-Square df Sig. 
(Intercept) .333 .2517 -.161 .826 1.748 1 .186 
[Group=0] -.315 .1143 -.539 -.091 7.578 1 .006 
[Group=1] 0a             
[Gender=0] 
.019 .1103 -.197 .235 .030 1 .863 
[Gender=1] 
0a             
[Race=1] .142 .2141 -.278 .561 .438 1 .508 
[Race=2] .193 .2190 -.236 .623 .781 1 .377 
[Race=3] -.045 .2851 -.604 .514 .025 1 .874 
[Race=4] 0a             
Age_Baseline 
-.016 .0118 -.039 .007 1.857 1 .173 
(Scale) .314b .0405 .244 .404       
Dependent Variable: Difference between Pre_IP_visits_count and Post_IP_visits_count 
Model: (Intercept), Group, Gender, Race, Age_Baseline   
b. Maximum likelihood estimate.     
 
 
The chi square statistic is smaller than its df (Table 6.23) and is nearing zero. Therefore, 
observed values nearly equal expected values, and confirm the validity of the model. 
 
Table 6.23: Multivariate Results GLM: Change in Utilization of Asthma-related IP stays between 
Pre and Post Period: Goodness of Fit 
 
  Value df Value/df 
Pearson Chi-Square 37.68 113 0.33 
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Outpatient Visits 
There was almost a statistically significant change in the overall utilization of asthma-
related outpatient visits (Table 6.24) between the control and intervention group 
between the two periods (P =.068). The slope coefficient for the dependent variable is 
group is negative, indicating that going from control group to intervention group 
decreases the change in utilization of the number of asthma-related outpatient visits. 
The gender predictor is also positive, indicating that going from male to female 
increases the change in utilization of asthma-related scripts, although the change is not 
statistically significant. The race variables for black (race =1), white (race =2) and 
Hispanic (race=3) are also positive, indicating an increased change in utilization as 
compared to the ‘other’ category, but it is not statistically significant.  The Hispanic 
group (race = 3) coefficient is negative, indicating a decrease in change in utilization as 
compared to the ‘other’ race group. Age at baseline is not statistically different between 
the intervention and control groups, but indicates a small positive effect on a change in 
utilization of asthma-related outpatient visits overall. 
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Table 6.24: Multivariate Results GLM: Change in Utilization of Asthma-related OP visits between 
Pre and Post Period 
Parameter estimates 
      Interval Hypothesis Test 
Parameter B S.E. Lower Upper Wald Chi-Square df Sig. 
(Intercept) -.398 .8740 -2.110 1.315 .207 1 .649 
[Group=0] -.725 .3970 -1.503 .053 3.336 1 .068 
[Group=1] 0a             
[Gender=0] 
.500 .3829 -.250 1.251 1.706 1 .192 
[Gender=1] 
0a             
[Race=1] .575 .7433 -.882 2.032 .598 1 .439 
[Race=2] 1.015 .7601 -.474 2.505 1.784 1 .182 
[Race=3] .073 .9899 -1.867 2.013 .005 1 .941 
[Race=4] 0a             
Age_Baseline 
.020 .0408 -.060 .100 .250 1 .617 
(Scale) 3.784b .4886 2.938 4.874       
Dependent Variable: Difference between Pre_OP_Visits and Post_OP_Visits 
Model: (Intercept), Group, Gender, Race, Age_Baseline     
b. Maximum likelihood estimate.         
 
 
     
The chi square statistic is larger than its df (Table 6.25). Therefore, observed values 
deviate significantly from expected values, and indicate that the model is not optimum. 
 
Table 6.25: Multivariate Results GLM: Change in Utilization of Asthma-related OP visits between 
Pre and Post Period: Goodness of Fit 
 
  Value df Value/df 
Pearson Chi-Square 454.13 113 4.02 
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Summary 
In summary, the change in inpatient visits is statistically significant at p<.05 (C=-0.00, 
I=0.32, p=.006) and the change in outpatient visits is borderline significant at p<.10 (C=-
0.33, I=0.39, p=.068) (Table 6.26). The change in outpatient visits had not been 
significant when not adjusting for age at baseline, race and gender (Table 6.7). 
There was a statistically significant change in the overall utilization of asthma-related 
controller prescriptions between the two groups, which remained significant when 
adjusting for age at baseline, race and gender (Table 6.16). 
 
Table 6.26: Multivariate Results Change in Utilization of Asthma-related services and care between 
Pre and Post Period 
 
 
Costs 
General linear regression was used to determine any changes in total medical care 
costs during the pre and post periods, adjusting for age at baseline, race, and gender.  
The mean and standard error were reported for the control and intervention group, and 
Beta
Mean Std. Error Mean Std. Error P-Value
Change in Prescriptions Filled 1.05 -0.85 0.80 -1.90 0.95 0.313
Change in ED visits -0.08 1.11 0.23 1.19 0.27 0.783
Change in IP visits -0.31 0.00 0.09 0.32 0.10 0.006
Change in OP visits -0.73 -0.33 0.31 0.39 0.36 0.068
Dependent Variable: Difference;  Significance at .05
Model: (Intercept), Group, Gender, Race, Age_Baseline
 
 
            
CONTROL INTERVENTION
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a significance test at p <.05. None of the medical cost types, individually or in unison, 
showed a statistically significant difference over the two time periods (Table 6.27).   
 
Table 6.27:  Multivariate Results Adjusted Costs of Asthma-related Care among HHU II 
participants and a control group 
 
 
There was virtually no change in the overall total cost of asthma-related medical care 
(Table 6.27) between the control and intervention group between the two periods 
(C=$1280, I=$1276, P=.996). The slope coefficient for the dependent variable group is 
positive, indicating that going from control group to intervention group increases the 
overall asthma-related medical costs by $4 (Table 6.28). The gender predictor is also 
negative by $595, indicating that going from male to female decreases the change in 
utilization of asthma-related scripts, although the change is not statistically significant. 
The race variables for black (race =1), white (race =2) and Hispanic (race=3) are all 
negative, indicating an increased change in utilization as compared to the ‘other’ 
category, but it is not statistically significant.  Age at baseline is not statistically different 
Coefficient S.E.
Mean Std. Error Mean Std. Error P-Value*
RX Costs $104 113.23 -85.16 87.64 -188.72 103.62 0.360
ED Costs -$50 83.584 301.56 64.70 351.20 76.49 0.553
IP Costs -$31 727.19 1076.72 562.88 1108.07 665.50 0.553
OP Costs -$18 35.935 -13.35 27.82 5.10 32.89 0.608
Total Medical Costs $4 742.24 1279.77 574.53 1275.65 679.27 0.996
Dependent Variable: Difference;  Significance at .05
Model: (Intercept), Group, Gender, Race, Age_Baseline
 
 
            
INTERVENTIONCONTROL
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between the intervention and control groups, but indicates a small negative effect on the 
overall change in costs of asthma-related care. 
 
Table 6.28: Multivariate Results GLM: Change in Costs of Asthma-related Medical Care between 
Pre and Post Period 
 
 
The chi square statistic is extremely large, thousands of times larger than its df (Table 
6.29). Therefore, observed values deviate significantly from expected values, and 
indicate that the model is not predictive at all. 
 
Parameter B S.E. Lower Upper Wald Chi-Square df Sig.
(Intercept) 2866.181 1634.1630 -336.720 6069.081 3.076 1 .079
[Group=0] 4.130 742.2435 -1450.641 1458.900 .000 1 .996
[Group=1] 0a
[Gender=0]
-594.859 715.9639 -1998.122 808.404 .690 1 .406
[Gender=1]
0a
[Race=1] -933.033 1389.9127 -3657.212 1791.145 .451 1 .502
[Race=2] -530.442 1421.3622 -3316.260 2255.377 .139 1 .709
[Race=3] -1671.769 1850.9314 -5299.528 1955.990 .816 1 .366
[Race=4] 0a
Age_Baselin
e
-83.491 76.3770 -233.187 66.205 1.195 1 .274
(Scale) 13231773.353b 1708214.5945 10273736.115 17041495.332p     _   _   _   _
Model: (Intercept), Group, Gender, Race, Age_Baseline
a. Set to zero because this parameter is redundant.
b. Maximum likelihood estimate.
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Table 6.29: Multivariate Results GLM: Change in Costs of Asthma-Rescue RX filled between Pre 
and Post Period Goodness of Fit 
 
Utilization 
A comparison of means for the change in utilization between the two control and 
intervention groups was conducted. There were no statistically significant changes in 
means of utilization between the two groups with the outliers removed (Table 6.30). 
The dataset had a non-normal distribution.  For this analysis, for each type of medical 
care (RX scripts filled, emergency department visits, inpatient stays, and outpatient 
visits) the extreme observations were excluded.  For each variable of interest, outliers 
were removed for that specific interest area, and noted in the table (Table 6.30).   
 
Value df Value/df 
Pearson Chi-Square 1587812802.31 113 14051440.73 
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Table 6.30: Comparison of Means of Utilization of Asthma-related Services and Care between Pre 
and Post Period with Exclusion of Outliers 
 
 
Costs 
Similarly, a comparison of means for the change in costs between the two groups was 
conducted, with the respective outliers removed for each variable of interest in the 
analysis (Table 6.31). With all the outliers removed, the total difference in change of all 
medical costs together approached significance at p<.1, (C=$470, I=968, p=.110).  The 
intervention group cost $498 per case less on medical costs than the control group. 
# outliers
 removed Mean S.E. Mean S.E. p-value*
Change in Prescriptions Filled 2 -0.10 0.54 -1.29 0.93 0.240
Change in Number of Emergency Department V 1 0.84 0.14 0.78 0.26 0.838
Change in Number of Inpatient Visits n/a
Change in Number of Outpatient Visits 1 -0.01 0.16 0.74 0.46 0.127
NOTE:  Removed the following cases for this analysis: *Significance at .05
Inpatient Stays: none
Prescriptions Filled: Case 38, 115 (Pre>25, Post >27)
Emergency Department Visits: Case 57,( Pre > 5)
Outpatient Visits:  Case 113, (Post > 7)
INTERVENTIONCONTROL
Not calculated no outliers excluded
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Table 6.31: Comparison of Means of Asthma-Related Costs with Exclusion of Outliers 
 
 
6.3.5. General linear regression with exclusion of outliers 
Costs 
General linear regression was used to determine any changes in medical care costs 
during the pre and post periods, adjusting for age at baseline, race, and gender.  The 
mean and standard error were reported for the control and intervention group, and a 
significance test was conducted at p <.05.  Each of the types of medical care were run 
separately.  One of the medical cost types, inpatient costs, showed a statistically 
significant difference over the two time periods with the outliers removed (C=$513, 
I=$1207, p<.042).  The difference in total medical costs was close to statistical 
significance (C=$347, I=$946, p<.052), with the intervention group saving $620 over the 
control group during the two time periods, with the outliers excluded (Table 6.32). The 
individual regression tables for each cost type are presented as follows: RX costs 
(Table 6.33), ED costs (Table 6.34), IP costs (Table 6.35), and overall Medical costs 
# outliers P-Value Benefit
removed Mean S.E. Mean S.E.
Difference between Post and  Pre Period RX Costs 1 $10 53.45 -$149 313.07 0.26 -$160
Difference between Post and  Pre Period ED Costs 1 $236 43.90 $256 81.34 0.66 $20
Difference between Post and  Pre Period IP Costs 2 $399 181.35 $964 104.54 0.08 $564
Difference between Post and  Pre Period OP Costs 0
Total Difference in Post and  Pre Medical Costs 5 $470 168.80 $968 279.15 0.11 $498
Total Medical Costs:  Case 20,38,47,59,67 (Pre >$15,000, Post, >$7000)
NOTE:  Removed the following cases for this analysis:
Prescription Costs: Case 38 (Pre>$5700, Post>$7700)
Emergency Department Costs:  Case 39 (Post>$1800)
Inpatient Costs: Cases 59,67 (Pre=>$25,000)
Outpatient Costs: None
          
CONTROL INTERVENTION
Not calculated no outliers excluded
 
  
120 
 
(Table 6.36).  
 
Table 6.32: Multivariate Results Adjusted Costs of Asthma-related Care among HHU II participants 
and a control group with outliers removed 
 
  
# Outliers removed Beta S.E.
Mean S.E.  Mean S.E. P-Value* Difference
RX Costs 1 -137.31 108.04 -$64 83.49 -$201 98.59 0.204 -$137
ED Costs 1 61.27 84.60 $298 64.87 $359 77.02 0.469 $61
IP Costs 2 693.82 341.72 $513 265.12 $1,207 311.43 0.042 $694
OP Costs n/a
Total Costs 5 619.62 318.90 $347 254.36 $966 295.09 0.052 $620
Dependent Variable: Difference;  Significance at .05
Model: (Intercept), Group, Gender, Race, Age_Baseline
CONTROL INTERVENTION
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Table 6.33: Multivariate Results Difference between Pre-RX Costs and Post-RX Costs of Asthma-
related Care among HHU II participants with RX outliers removed 
       
Dependent Variable: Difference between 
Pre_RX_Costs  and Post_RX_Costs 
Model: (Intercept), Group, Race, Gender, 
Age_Baseline     
        
Parameter Estimates 
Parameter 
B Std. Error 
95% Wald Confidence 
Interval Hypothesis Test 
Lower Upper 
Wald 
Chi-
Square df Sig. 
(Intercept) -411.403 237.1390 -876.187 53.380 3.010 1 .083 
[Group=0] 137.311 108.0414 -74.447 349.068 1.615 1 .204 
[Group=1] 0a             
[Race=1] 143.703 201.6418 -251.508 538.914 .508 1 .476 
[Race=2] 131.507 206.8701 -273.951 536.965 .404 1 .525 
[Race=3] -61.599 268.6554 -588.154 464.956 .053 1 .819 
[Race=4] 0a             
[Gender=0] 
37.992 103.9730 -165.792 241.775 .134 1 .715 
[Gender=1] 
0a             
Age_Baseline 
22.422 11.1324 .603 44.241 4.057 1 .044 
(Scale) 278363.611b 36087.2658 215904.681 358891.244       
Dependent Variable: Difference between Pre_RX_Costs  and Post_RX_Costs 
Model: (Intercept), Group, Race, Gender, Age_Baseline 
     a. Set to zero because this parameter is redundant. 
     b. Maximum likelihood estimate. 
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Table 6.34: Multivariate Results Difference between Pre-ED Costs and Post-ED Costs of Asthma-
related Care among HHU II participants with ED outliers removed 
        
Dependent Variable: Difference between Pre_ED_Costs and 
Post_ED_Costs 
Model: (Intercept), Group, Race, Gender, Age_Baseline     
        
Parameter Estimates 
Parameter 
B Std. Error 
95% Wald Confidence 
Interval Hypothesis Test 
Lower Upper 
Wald 
Chi-
Square df Sig. 
(Intercept) 742.134 184.4103 380.697 1103.572 16.196 1 .000 
[Group=0] -61.268 84.6054 -227.091 104.556 .524 1 .469 
[Group=1] 0a             
[Race=1] -517.379 156.8197 -824.740 -210.018 10.885 1 .001 
[Race=2] -482.928 160.1776 -796.871 -168.986 9.090 1 .003 
[Race=3] -602.933 208.6500 -1011.880 -193.987 8.350 1 .004 
[Race=4] 0a             
[Gender=0] 
-.385 80.8313 -158.811 158.042 .000 1 .996 
[Gender=1] 
0a             
Age_Baseline 
2.930 8.6305 -13.985 19.845 .115 1 .734 
(Scale) 168025.181b 21782.9096 130323.871 216633.080       
Dependent Variable: Difference between Pre_ED_Costs and Post_ED_Costs 
Model: (Intercept), Group, Race, Gender, Age_Baseline 
a. Set to zero because this parameter is redundant. 
b. Maximum likelihood estimate. 
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Table 6.35: Multivariate Results Difference between Pre-IP Costs and Post-IP Costs of Asthma-
related Care among HHU II participants with IP outliers removed 
       
Dependent Variable: Difference between Pre_IP_Costs and 
Post_IP_Costs 
Model: (Intercept), Group, Race, Gender, Age_Baseline     
        
Parameter Estimates 
Parameter 
B Std. Error 
95% Wald Confidence 
Interval Hypothesis Test 
Lower Upper 
Wald 
Chi-
Square df Sig. 
(Intercept) 2662.346 751.3301 1189.766 4134.926 12.556 1 .000 
[Group=0] -693.823 341.7182 -1363.579 -24.068 4.123 1 .042 
[Group=1] 0a             
[Race=1] -1073.866 637.9945 -2324.312 176.580 2.833 1 .092 
[Race=2] -921.787 652.8117 -2201.274 357.701 1.994 1 .158 
[Race=3] -1525.825 848.5729 -3188.997 137.347 3.233 1 .072 
[Race=4] 0a             
[Gender=0] 
-358.131 333.0459 -1010.889 294.627 1.156 1 .282 
[Gender=1] 
0a             
Age_Baseline 
-64.561 35.3168 -133.781 4.658 3.342 1 .068 
(Scale) 2778670.276b 361752.0573 2152880.943 3586361.118       
Dependent Variable: Difference between Pre_IP_Costs and Post_IP_Costs 
Model: (Intercept), Group, Race, Gender, Age_Baseline 
a. Set to zero because this parameter is redundant. 
b. Maximum likelihood estimate. 
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Table 6.36: Multivariate Results GLM: Change in Costs of Asthma-related Medical Care between 
Pre and Post Period with outliers removed 
 
  
 
     
 Dependent Variable: Sum of Benefit_OP + Benefit_IP 
+ Benefit_ED + Benefit_RX 
Model: (Intercept), Group, Race, Gender, 
Age_Baseline     
         
 Parameter Estimates 
Parameter 
B Std. Error 
 95% Wald Confidence 
Interval Hypothesis Test 
 
Lower Upper 
Wald 
Chi-
Square df Sig. 
(Intercept) 1436.792 741.8072  -17.123 2890.708 3.752 1 .053 
[Group=0] -619.619 318.8962  -1244.644 5.406 3.775 1 .052 
[Group=1] 0a              
[Race=1] -237.156 629.3012  -1470.564 996.252 .142 1 .706 
[Race=2] -188.006 642.8375  -1447.944 1071.932 .086 1 .770 
[Race=3] -976.243 811.8837  -2567.505 615.020 1.446 1 .229 
[Race=4] 0a              
[Gender=0] 
-34.460 313.5807 
 
-649.067 580.147 .012 1 .912 
[Gender=1] 
0a   
 
          
Age_Baselin
e -16.478 32.8900 
 
-80.942 47.985 .251 1 .616 
(Scale) 2365594.467b 311965.3599  1826783.837 3063327.510       
 Dependent Variable: Sum of Benefit_OP + Benefit_IP + Benefit_ED + Benefit_RX 
Model: (Intercept), Group, Race, Gender, Age_Baseline 
 a. Set to zero because this parameter is redundant. 
 b. Maximum likelihood estimate. 
 
 
There was no statistical significance of age, gender, or race on the RX costs, OP costs, 
and IP costs models.  However, for the emergency department costs, race was a 
significant factor in the model. Therefore, the model for total medical costs was run 
again controlling for race only (Table 6.37).  In that model, the difference in total medical 
costs was statistically significance (C=$337, I=$962, p<.05), with the intervention group 
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saving $624 over the control group during the two time periods, with the outliers 
excluded (Table 6.37). 
 
Table 6.37: Multivariate Results Adjusted Costs of Asthma-related Care among HHU II participants 
and a control group 
 
 
6.3.6. Comparisons of Costs Calculations 
6.3.6.1. Overall Effect on Medical Costs 
When considering the various cost calculations, it is evident that the healthy homes 
intervention makes very little difference on the overall medical costs incurred (Table 
6.38).  The unadjusted net benefit is an increase in medical costs of $156, which is not 
statistically significant (Table 6.13). When a regression model is used, the intervention 
costs $4 more than the control, and the difference is not statistically significant (Table 
6.27).   When outliers are removed, the unadjusted net benefit is a savings of $498, but 
the difference between the groups is not significant (Table 6.31).  When outliers are 
removed and a regression model is used, the savings increases to $620 and the model 
approaches significance at p=<.05 (Table 6.32).   A final regression model with outliers 
# Outliers removed Beta S.E.
Mean S.E. Mean S.E. P-Value* Difference
Total Medical Costs 5 -$624 319.05 337.90 243.87 962.39 285.28 0.05 $624
Model: (Intercept), Group, Race
Dependent Variable: Difference;  Significance at .05
CONTROL INTERVENTION
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removed which only controls for race, which had been a significant predictor, accounts 
for a final savings of $624, which is statistically significant at p=<.05 (Table 6.37). 
 
Table 6.38: Comparison of Total Medical Cost Calculations and Net Benefit 
 
 
 
Table 6.39 represents the average marginal direct and full per person cost for the 
Healthy Homes University II program participants.  
 
Table 6.39: Healthy Homes University II Average per-Person Marginal, Direct, and Full Costs 
 
            
    Cost Per Program participant   
Marginal $1,882     
Direct $3,751     
Full $4,832     
 
 
The difference between the total benefit and the marginal, direct, and full costs were 
calculated and are displayed in Table 6.40. 
 
P-Value* Net Benefit
Mean S.D. Mean S.D.
Unadjusted Change in Costs (Table 6.13) $1,241 4342 $1,085 1875 0.240 -$156
Adjusted Change in Costs - Regression (Table 6.27) $1,280 575 $1,276 679 0.996 -$4
Unadjusted Change in Costs with outliers removed (Table 6.31) $470 169 $968 279 0.11 $498
Adjusted Change in Costs with outliers removed- Regression (Table 6.32) $347 254 $966 295 0.052 $620
Adjusted Change in Costs with outliers removed- Regression (Table 6.37) $338 244 $962 285 0.5 $624
*Significant at p=<.05
CONTROL INTERVENTION
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Table 6.40: Effect of Marginal, Direct, and Full Costs on Net Benefit 
 
 
 
For all scenarios, there is no cost benefit to conducting this healthy homes intervention 
if evaluating against a potential savings in asthma related medical costs.  When 
compared against the marginal project costs, the benefit ranged from -$1,258 (in a 
model removing the outliers) to -$2,038 (in a model of unadjusted costs). 
When compared against the direct project costs, the benefit ranged from -$3,127 (in a 
model removing the outliers) to -$3,907 (in a model of unadjusted costs). 
When compared against the full project costs, the benefit ranged from -$4,208 (in a 
model removing the outliers) to -$4,988 (in a model of unadjusted costs). 
 
 
  
P-Value* Net Benefit Benefit  minus Benefit minus Benefit minus
Marginal Cost ($1882) Direct Cost ($3751)  Full Cost($4832)
Unadjusted Change in Costs (Table 6.13) 0.240 -$156 -$2,038 -$3,907 -$4,988
Adjusted Change in Costs (Table 6.27) 0.996 -$4 -$1,886 -$3,755 -$4,836
Unadjusted Change in Costs without outliers (Table 6.31) 0.11 $498 -$1,384 -$3,253 -$4,334
Adjusted Change in Costs without outliers (Table 6.32) 0.052 $620 -$1,262 -$3,131 -$4,212
Adjusted Change in Costs without  outliers (Table 6.37) 0.5 $624 -$1,258 -$3,127 -$4,208
*Significant at p=<.05
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Chapter 7 
Discussion and Policy Implications 
Little is known about the cost-benefit of Health Homes Intervention programs to control 
chronic diseases such as asthma in Michigan.  Current reimbursement agreements do 
not cover the full costs of asthma prevention programs, and none of the existing 
program in Michigan include best practice 4, the implementation of environmental 
control measures.  One group, the Asthma Network of West Michigan (ANWM) has 
provided home-based case management services to Priority Health’s Medicaid pediatric 
population on a fee-for-service basis, and also has contracts with four other health 
plans.  The goal of this study was to evaluate the cost implications of an asthma healthy 
homes intervention in Michigan. The anticipated findings were improved health 
outcomes and lower health care costs for children with asthma in Michigan. 
7.1. Discussion 
7.1.1. Utilization 
The study considered the change in utilization for four types of health care in children 
with asthma who participated in the study: asthma controller and reliever use; 
emergency department visits; inpatient stays; and outpatient visits.  The intervention 
group had higher rates of utilization for all types of medical care during the pre-period, 
therefore it also had bigger potential for gains in reducing utilization. 
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Prescription Use 
There was a statistically significant difference in the change in asthma controller use, 
with the intervention group increasing its use of controller medications four times as 
much as the control group (Chapter 6; Tables 6.7, 6.16). The intervention group 
increased its use of rescue medication more than the control group, although the finding 
was not significant (Chapter 6, Table 6.18).  These findings compare to the Kattan study 
(2005), where participants increased their use of anti-inflammatory medication and 
cromolyn inhalers; in that study they also decreased their use of inhalers used per year 
by 2.  The fact that controller medications increased significantly in the intervention 
population shows that the educational components of the intervention was effective. 
Emergency department visits 
There was no significant decrease in asthma-related emergency department use 
between the groups. Other studies have found decreases in emergency department 
use, such as Kercsmar (2006), Krieger (2005), Kattan (2005), and Sullivan (2002). The 
Kattan, Kreiger, and Sullivan studies were randomized controlled trials which all 
included minor rehabilitative work; the Krieger study compared a high intensity 
intervention against a low intensity intervention, and the Sullivan study was focused on 
education and self-management, delivered by Asthma counselors.   
Inpatient utilization 
There was a statistically significant decrease in the mean number of inpatient stays; the 
intervention group started off with higher relative number (twice as many) of IP stays 
than the controls,  and reduced it to 1/4 as many, a very significant reduction (Chapter 
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6; Tables 6.7, 6.22). The intervention group experienced half as many stays during the 
post-intervention period as the control group.  This finding was consistent with Kercsmar 
(2005) and Krieger (2005), whose findings were also statistically significant, and also 
with Kattan (2005) and Sullivan (2002), with similar findings but which were not 
statistically significant. 
Outpatient utilization 
The intervention group started off with three times as many outpatient visits as the 
control group, and  reduced to twice as outpatient visits as the control group, which was 
more than proportional, although not statistically significant. The Generalized Linear 
Model approached significance at p=<.068 (Chapter 6, Table 6.24). Outman (2007) 
demonstrated a statistically significant reduction in unscheduled visits in the evaluation 
of an intervention that provided basic remediation, coupled with visits by an asthma 
educator/respiratory therapist. Krieger (2005) also demonstrated a statistically 
significant reduction in unscheduled clinic visits. 
Other utilization considerations 
In the Michigan Asthma Call-Back survey [21], 51% of children with current asthma had 
not used a long term controller medication in the past 3 months.  The fact that the HHUII 
study had a significant impact on the use of long-term controllers (Chapter 6, Table 
6.12) is an important and desired finding, as the unadjusted change in the costs of 
controller medications approached significance (C=$57, I=$260, P=<.055).  A stated 
goal of the study was to determine if it had a decreasing effect on the cost of rescue 
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medications; unfortunately, these costs increased for the intervention group, but not for 
the control group, but the finding was not significant.   
7.1.2. Medical Costs 
Emergency Department Costs 
There was no significant difference in the change of the mean cost of asthma-related 
ED visits. In a general linear model of emergency department visits, race was a 
significant factor in explaining variation in ED visits.  
Inpatient Costs 
There was no significant difference in the change of the mean cost of asthma-related IP 
stays. A generalized linear model showed statistical significance of inpatient costs with 
the removal of outliers ($C=$513, I=$1207, p<.042) (Table 6.32). 
Outpatient Costs 
There was no significant change in the mean cost of asthma related outpatient visits. 
Total Medical Costs 
Krieger (2005), Kattan (2005), and Sullivan (2002) all showed a range of medical costs 
averted between $124 and $155, compared with program costs which ranged between 
$458 and $1316.   In the HHUII study, none of the medical cost types showed a 
statistically significant difference in cost in either direction after the intervention, in fact 
there was virtually no change (C=$1289, I=$1276, p=.996), with the intervention group 
costing $4 more (Table 6.27). With the outliers removed, the total difference in change 
of all the medical costs together approached significance at p=<.1 (C=$470, I=$968, 
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p=.110), a savings of $498 more for the intervention group (Table 6.31). A generalized 
linear model of total medical costs was close to statistical significance with the outliers 
removed ($C=$347, I=$946, p<.052) (Table 6.32), a savings of $620 for the intervention 
group. When a general linear model with outliers removed was run for medical costs 
controlling for race only, the difference was significant, with the intervention saving $624 
over the control group(C=$337, I=$962, p=<.05) (Chapter 6, Table 6.37).  These results 
are comparable to the Krieger (2005), Kattan (2005), and Sullivan (2002) results. 
7.1.3. Other cost considerations  
Quality of Life 
A major limitation of this study was its ability to quantify and assign a value to the effects 
that the intervention had on quality of life.  The asthma call-back survey [21] provides a 
comprehensive look at the current effect asthma is having on children’s quality of life in 
Michigan; 17% of children experience symptoms 9+ days per month; 10% of children 
have difficulty sleeping  2+ days per month; 12% of children experience asthma every 
day of the past two weeks; 55% of children limited usual activities due to asthma during 
the past 12 months; 17% of children missed 6 or more school days in the past 12 
months. 
In the HHU II study [55], caregivers did report monthly frequencies for subject children 
experiencing negative health effects due to asthma as shown in Figure 7.1.  
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Figure 7.1*: Median Number of Days of Symptoms in Past Month 
 
Median number of days of symptoms in the past month at Baseline and Six-months. 
Figure* provided by Healthy Homes University II,  [55] 
 
 
Quality of life was assessed using the caregiver version of the validated Asthma Quality 
of Life Questionnaire (AQLQ). The Caregiver AQLQ [56] contains 13 questions and 
response categories range from 1 (All of the time or very, very worried/concerned) to 7 
(None of the time or Not worried/concerned). The score was calculated for both 
Baseline and Six-months. If a person’s median score improves by 0.5, it is considered a 
significant indicator of improvement.  All of the findings were based on self-report.  For 
each of the listed indicators of asthma impact, the number of monthly occurrences 
reported at six months was less than reported at baseline with the exception of missed 
school and work days.  The reductions seen in the proportion of individuals morning 
wheezing; nights awakened; shortness of breath, wheezing, tightness in chest or cough; 
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or activity limitation were statistically significant (P<.005, P<.0001, P<.0001 and 
P<.0001, respectively).   
School and Work days missed 
The HHU II program reported [55] a 0.5 day reduction in the mean number of days 
missed from school due to asthma in the six-months prior to completion as compared to 
the six-months prior to Baseline, however, this reduction was not statistically significant. 
Only 73 of the 183 participants reported that they worked outside the home. There was 
no change in median number of missed work days from Baseline to Six-months (Figure 
7.1). 
Caregiver participants also reported questions pertaining to their quality of life. There 
was a statistically significant increase in emotional function and decreases in activity 
limitation (Figure 7.2).  
 
Figure 7.2*: Asthma Quality of Life Survey 
 
Caregiver participant pre/post asthma quality of life mean number of days score results 
(N=164). Figure* provided by Healthy Homes University II,  [55] 
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7.1.4. Cost-benefit considerations 
The study did not find a net change in the costs of asthma related medical care.  The 
finding were flat (-$4).  With outliers removed, the net change in the costs of asthma 
related medical care was $624. These findings are consistent with the findings of 
previous researchers (Table 7.1)  who have attempted to demonstrate the cost-benefit 
of healthy homes interventions in programs with minor (provision of advice on 
recommended environmental changes and may include provision of low-cost items such 
as mattress and pillow allergen-impermeable covers) or moderate (provision of low cost 
materials, active involvement of a trained home visitor, installation of low-cost items 
including sair filters and dehumidifiers, integrated pest management, professional 
cleaning services, and minor repairs of structural integrity) environmental trigger 
education and mitigation [57-59].  All three studies had a benefit-cost ration between 0.9 
and 0.32, indicating that the program costs were significantly more than the direct 
medical costs averted, which ranged from $124-$555. 
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Table 7.1: Results of Selected Studies of Home-based, Multi-Component Environmental 
Interventions to Reduce Asthma Morbidity* 
 
 
Quality of life measures made in this study did not measure symptom free-days.  
Assuming that symptom-free days measures were available, at a benefit of $20 per 
symptom-free day, participant in the program would have to have  94 ($1882 divided by 
$20) symptom free days per year,  which were previously not symptom free, in order to 
make a case for the costs effectiveness of the study based on that criteria. 
Some studies have reported benefit-cost ratios ranging from 5.3-14.0 [60-62].  All three 
of those studies were pre-post design, and had very low ($377-721) program costs per 
participant. The Oatman, Jowers, and Shelledy studies had a strong focus on certified 
asthma educators, nurses, or respiratory therapists providing patient education, with a 
Study Program Cost ($) Direct medical costs averted ($) Net Cost ($)
Studies with major rehabilitation work
Barton (2007) $14,858 Not reported
Sommerville (2000) $6,424 Not reported
Kercsmar(2006) $3,796 Not reported
Studies with minor rehabilitation work
Krieger(2005) $1,316 $124-$147 $1192-$1169
Kattan (2005) $1,720 $555 $1,165
Sullivan (2002) $458 $147 $311
Healthy Homes University II 
Adjusted costs $1,882 -$4 $1,886
Adjusted costs without outliers $1,882 $624 $1,258
*Studies summarized by Nurmagambetov, 2011, except for present HHU II study
Summary of Per-Participant Economic Information
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level of intensity through home visits or phone follow-up.  This was a significant variation 
from the Healthy Homes University II program model. 
7.2. Limitations 
There were several limitations to the study which may affect the generalizability of the 
results.  
Recruitment Criteria 
The Healthy Homes University II project was funded by HUD, and had a recruitment 
goal of two hundred fifty participants.  HUD required that a benchmark of a set number 
of cases be conducted quarterly. Recruitment criteria included having at least one self-
reported ED or inpatient hospitalization, or two unscheduled doctor visits and four SABA 
fills in the 12 months prior to recruitment. However, if the reporting period was coming to 
a close and the benchmark wasn’t met, then the program would lessen the eligibility 
requirements for enrollment, and it would be based on control (symptomology) instead 
of severity or persistence; if the benchmark wasn’t met, the program was at risk for a 
low score that quarter, which would affect future funding opportunities. The attrition 
table (Chapter 5, Table 5.1) illustrates that only 40 of the 240 participants in Lansing 
met the ED or hospitalization criteria and 24 months of continuous enrollment in 
Medicaid, once their claims data was matched with the Medicaid database, and thus 
were eligible for the cost-benefit study.  This small sample could be due to the fact that 
the program had challenges meeting their recruitment goals, and towards the end of 
each reporting period, the project enforcement of the required ED or hospitalization 
requirement to be in the study was not as stringent as the outset.  This compromised 
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the strength and integrity of the study, as only one-sixth of the program participants 
ended up in the cost-benefit study. The representative nature of the sample as 
compared to the entire HHU II population can be questioned.  Also, a question is 
introduced: did the 210 program participants who did not qualify for the study really 
have asthma?  If they did not, they presumably would have had even lower levels of 
emergency department visits and inpatient stay, and an even lesser effect on costs. 
Effect of recruitment criteria on number of controller and reliever medications filled 
Anyone who has experienced a severe asthma event which resulted in emergency 
department use or an inpatient stay, will as a matter of course leave the hospital with 
asthma scripts for controller and reliever medications. The fact that those scripts are 
filled does not indicate whether they were used or not. Also, the experience of 
emergency department visits and/or hospitalizations may have an effect on proper 
adherence to the use of the indicated medications.  Therefore, the findings may not be 
generalizable to the general HHU II population, especially those who may not have had 
a true emergency department visit or inpatient stay prior to enrollment in the program. 
Self-Report 
Participants were recruited based on meeting self-reported criteria,  self-reported ED or 
inpatient hospitalization, or two unscheduled doctor visits and four SABA fills in the 12 
months prior to recruitment. As the self-report was based on recollection, it may or may 
not have been accurate. There may also have been respondent bias that individuals 
may report what they believe the program staff wants to hear, and would make them 
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eligible to participate in the program. Future studies should be based on medically 
verified eligibility for enrollment. 
Use of claims data 
Administrative claims data only reflects events that have been billed and paid for.  If a 
participant received care outside of the state of Michigan, it would not be reflected in the 
dataset. Medications which may have been received as samples are not included in the 
costs and utilization data.   
A review of administrative claims served as a proxy for chart reviews. A doctor’s 
confirmation of asthma as documented in a chart review serves as the gold standard for 
documentation of asthma.  Events that were coded as respiratory could have been in 
effect asthma and may not have been counted. 
Continuous enrollment in Medicaid 
The study population, by virtue of their 25 months of continuous Medicaid enrollment, 
continually met a low income threshold for that entire period.  The utilization of services 
of a population going in and out of eligibility for Medicaid may indicate that population at 
some point may have had access to employer insurance, which may have affected 
outcomes.  The findings, based on those with continuous Medicaid enrollment, thus 
might not be generalizable to the entire HHU II population. 
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Price data 
The cost of services using 2014 dollars was applied to all utilization data.  In doing so, 
prices may have been overstated by using 2014 dollars. True costs occurred in 2008 
through 2011.  This is a bias towards showing a larger benefit.  
Self-selection into the study 
The intervention group self-selected into the HHU II program, and chose to participate in 
it, contingent on meeting the inclusion criteria.  By definition, these individuals may be 
more proactive than the general populations which was included in the control group.  
Intervention participants may have been hyper aware of their asthma, which may have 
accounted for more asthma related outpatient and ED visits than the intervention group, 
and a greater number of asthma related RX scripts being written and filled. 
Regional variation 
The intervention region (Lansing) may have had a greater amount of physician training 
related to asthma management than the control regions (Kalamazoo and Jackson), 
which may explain the initial differences between the control and intervention groups.  
Quantity of the intervention 
The quantity of the intervention differed between the participants.  All received 
components of a baseline intervention, with basic services based on identified needs, 
and a limited number received a custom intervention, which was more extensive. 
Finally, a few benefited from partner interventions, which were typically more extensive 
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and in addition to the basic and custom services that were provided to all.  These 
varying quantities of intervention were not accounted for in the study. 
Emergency department admissions and inpatient admissions 
A number of cases (under 10) represented individuals which presented themselves and 
received services at the emergency room, and then were admitted into the inpatient 
unit.  These cases were counted in both categories, as from a cost perspective there 
were charges to both types of care. 
Selection of control population 
Controls were chosen from two comparable Michigan cities which had not received any 
known healthy homes interventions, Kalamazoo and Jackson, in order to ensure that 
the control population was not ‘contaminated’ with healthy homes information or 
messages.  Whereas this was done to neutralize bias, it may have introduced bias by 
choosing different cities with different populations, a different medical community, and 
varying patterns of utilization at the outset. 
Because asthma exacerbation is correlated with time of year, controls were frequency 
matched by the 25 month timeframe of the intervention group (12 months pre-
intervention month, the intervention month, 12 months post-intervention month). To 
allow for more flexibility in the analysis, this was the extent of matching when selecting 
controls.  In retrospect, matching on demographic information as well may have 
provided a better control population. 
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7.3. Policy Implications 
7.3.1. From an insurer perspective 
The objective of this study was to consider the cost-benefit of a healthy homes 
intervention project from an insurer/payer perspective.  The hypothesis that children 
with moderate to severe asthma who receive asthma education and environmental 
interventions in the home would have lower total medical costs related to lowered 
utilization of outpatient, emergency department, hospitalization, and use of rescue 
medications due to acute asthma events than children in a matched control group which 
do not receive any interventions was false.  Although there was a decrease in 
hospitalizations, and an increase in the use of controller medications, there was no 
significant change in the amount of total medical expenditures between the group which 
received the intervention, and the control group. A number of limitations have been 
explored, and thus the finding is not conclusive.   
These findings were consistent with other studies which did not show a cost-benefit for 
the intervention (Table 7.1).  Studies which have reported benefit-cost ratios ranging 
from 5.3-14.0 [60-62] had a strong focus on certified asthma educators, nurses, or 
respiratory therapists providing patient education, with a level of intensity through home 
visits or phone follow-up.  The model of patient education should be further investigated 
as a best practice which may justify a business case for paying for the service.  It may 
be that for any given patient population, if asthmatic patients are stratified based on 
diagnostic criteria and utilization of services, those in the highest risk group may benefit 
from asthma education and environmental trigger supplies as needed, and it may be 
cost-effective [24].  This model is being implemented in Michigan by the Asthma 
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Network of West Michigan, which is receiving fee-for-service payment for case 
management from Priority Health and four other Medicaid providers; however the 
reimbursement does not cover the full cost of the program [24]. 
Health Plans may be most concerned about the relative value of various health care 
services, and would be most concerned with the costs incurred in producing or 
arranging for medical care for their subscribers [36]. In that case, a lack of findings in 
any of the four cost categories of interest make the investment very difficult to justify 
from this perspective. Health plans are not as concerned about quality of life issues 
such as return to work, as they are not responsible for disability payments. 
Hoppin [24] suggests the following actions from public and private payers wishing to 
establish comprehensive asthma management programs: 1) establish incentives for 
providers to appropriately classify patients, monitor drug usage, and refer patients to 
clinical and in-home education sessions; 2)reimburse providers for asthma education 
delivered in clinical and home settings; 3) pay for supplies and services shown to 
improve self-management and reduce exposures to environmental triggers; 4) offer 
reimbursement mechanisms for the range of non-physician providers of asthma 
education and environmental services working in both clinical and community settings, 
including certified asthma educators; and 5) provide or reimburse for case management 
and outreach staff that complement quality primary care for high risk patients. Another 
key step is to identify what outcomes and outputs will be measured, and how they will 
be measured, so that program outcomes and results can be tracked [29]. 
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7.3.2. From other perspectives 
Employers expend 2.5 times as much for patients with asthma compared to those 
without the disease, predominantly on prescription medications [5].  Employers in 
general have not aligned their health benefits with the recommended best practices for 
asthma management, however they stand to gain from increased productivity, reduced 
employee absenteeism, and increased presenteeism.  They can promote 
comprehensive asthma management by securing coverage for asthma management 
services and supplies; offer asthma education through worksite health promotion 
programs;  offset expensive co-payments; and assess work conditions and exposures 
to promote safe working environments [24].   
Governmental entities such as the EPA note that as health plans pay a major portion of 
costs spent annually on asthma, they should consider incorporating asthma education 
and environmental interventions such as HHU II into their disease management 
approach [29] as access to these interventions remain scarce [24] .   
The goal of economic efficiency in public health is to “contribute to the highest 
attainment of public health... given available resources” [34]. Therefore, opportunities 
foregone because resources were allocated to a given strategy must also be taken into 
account. Public health often uses the societal approach, in which all significant costs 
and health effects associated with everyone affected by the intervention would be 
included in the analysis, regardless of the payer or benefactor [32], [33] and [36].  This 
approach would be consistent with the ‘Health in All Places’ (HIAP) public policy 
approach, which acts on the social and environmental factors that influence health but 
are out of the control of the health sector [39]. Currently, of the 18% of the U.S. gross 
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domestic product devoted to health care, 99% of those health care expenditures target 
individual medical care [12]. Very few resources are available to target public health and 
prevention programs that could benefit the entire population [36]. Pharmaceutical 
companies invest tens of millions to develop high tech and revenue-generating disease 
control strategies for asthma. As Krieger begs the question, “who will develop the high-
touch strategies (as was attempted in this program through home visiting and home 
remediation) which do not capture the interest of the pro-profit health care industry?” 
The annual cost for a year’s supply of inhaled fluticasone propionate (220 ug) is 
approximately $2200 per year, yet home visit programs are not reimbursed by health 
care payers [41]. The costs for such programs are up-front, and the benefits, if any, 
accrue over months or years.  The fact that home visit and home remediation benefits 
accrue over a long period of time does not encourage managed care organizations to 
pay for services for which they may not benefit from over the long-term.  
The Healthy Homes University II as currently structured does not provide good value for 
the money.  Resources should be directed to programs that provide better health 
outcomes per dollar to maximize health impact.  The program should be redesigned to 
provide better value (lower cost or better impact).  
7.4. Suggestions for Future Research 
Future studies should be based on medically verified eligibility for enrollment, and be 
limited to severe cases of asthma in order to have a chance to show any cost-savings.  
Individuals with severe asthma would presumably have higher utilization rates than 
those of individuals with controlled asthma, and would have the potential to make the 
savings worthwhile. 
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Determining which type of intervention will be most effective for which type of patient is 
important, and help determine what interventions are effective, as the least resource 
intensive interventions may be the most cost-effective [35].  This study did find that the 
intervention increased the use of controller medications, and decreased the number of 
hospitalizations.  It will be important to tease out the effect of the home visiting and 
education, versus the home remediation itself. Also, the effect of basic or custom 
remediation could be taken into account in future studies, as well as investigating if the 
age of housing, rental occupancy status, or caregiver education play a role in the 
outcome of the study. 
Future studies must be designed with the ability to identify controls which are from the 
same community to address a number of limitations which had been identified.  Ideally, 
this would be in the form of a randomized controlled trial. 
It is important that future studies to be able to measure and quantify symptom free days 
and also other quality of life factors.  If these variables are significant enough, they may 
be able to justify the costs of environmental remediation efforts, especially from an 
individual perspective.  
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